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ABSTRACT
Safety of therapeutics is one of the primary concerns during the treatment of any ailments.
Most of the toxic effects of drugs occurs due to accumulation of drug in organs, which is dependent
on the dosage of the drug. The ideal therapy should minimize the risk of causing adverse events at
the same time elicit intended therapeutic effects. Vigabatrin (VGB) is an antiepileptic drug used
primarily in the treatment of infantile spasms and it acts by inhibiting gamma amino butyric acid
(GABA) transaminase thereby increasing inhibitory neurotransmitter GABA levels. At therapeutic
doses, VGB accumulates in retina leading to peripheral visual field defects and retinal
degeneration. To alleviate retinal toxicity of VGB, different approaches have been explored to
decrease the ocular accumulation of VGB and to protect retina from deleterious effects of VGB.
Intranasal administration approach was investigated to deliver VGB directly to brain via
olfactory region. The in vivo acute, sub-acute and pharmacodynamic studies were performed in
Sprague Dawley rats by administering VGB through intraperitoneal and intranasal routes. The
mechanism of VGB transport across blood retinal barrier was studied using retinal epithelial cells
(ARPE-19) cells. The in vitro and in vivo studies were performed to evaluate the mechanism
involved in retinal uptake of VGB and identify approach to decrease VGB retinal uptake. The
effects of VGB on retinal neuronal (R28) and ARPE-19 cells were studied. The cytoprotective
effect of silymarin and taurine on VGB induced retinal toxicity was investigated.
The subacute intranasal administration decreased retinal VGB levels and histological
changes compared to intraperitoneal administration. Intranasal pharmacodynamic study
ii

demonstrated smaller dose produced significant antiepileptic activity with prolonged duration of
VGB action. The ARPE19 cellular transport studies showed Na+/Cl- dependent transporter, TauT
was involved in retinal VGB uptake. Further, in vitro cell uptake and in vivo SD rat studies
demonstrated TauT inhibitors decreased VGB retinal uptake, thus confirming role of TauT in
retinal uptake of VGB. The in vitro cell toxicity studies demonstrated, VGB treatment produced
cell death in ARPE19 and R28 cells are due to apoptosis and necrosis, respectively. Further, studies
demonstrated antioxidants silymarin and taurine constituents decreased VGB induced cell toxicity.
The study results demonstrate intranasal administration of VGB along with a safe TauT inhibitor
and an antioxidant as a supplement would be beneficial to prevent the VGB induced retinal
toxicity.
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ANOVA

Analysis of Variance

ARPE-19

Adult Retinal Pigment Epithelium

BRB
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CE
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2,7- dichlorodihydrofluorescein diacetate

DMEM

Dulbecco's Modified Eagle Medium
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Fetal Bovine Serum
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Gamma-aminobutyric acid
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HPLC
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JC-1

5,5’,6,6’-tetrachloro-1,1’,3,3’-tertraethylbenzimi-dazolylcarbocyanine
iodide

LLOQ

Lower Limit of Quantification

MBCP

Multiblock Copolymer
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
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2, 3- Naphthalene di carboxaldehyde

PTZ

Pentylenetetrazol
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Retinal Pigment Epithelium
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Solute Carrier Transporter
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Taurine Transporter

VGB
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CHAPTER 1
Introduction
Infantile spasm is an epileptic disorder in infancy and early childhood, commonly occurs
between 3 to 12 months of age. The symptoms of spasms involve a series of transient jerking
movements of arms and legs, which last for few seconds or occurs in clusters 1. The etiology of
infantile spasm involves complex mechanisms occurring in prenatal, perinatal or postnatal stages.
The major causes are central nervous system malformations, brain tumors, metabolic or genetic
syndromes. More than 70 percent of infantile spasms cases are associated with tuberous sclerosis
complex (TSC) syndrome2. TSC syndrome affects many parts of body leading to multiple
hamartoma formation in skin, brain, kidney, heart and lungs. Infantile spasms diagnosed using
electroencephalogram (EEG) usually shows specific pattern called hypsarrhythmia 3. Early
diagnosis and treatment in infants reduce risk of development into complex seizures.
Vigabatrin (VGB) an antiepileptic drug, acts by inhibiting Gamma-aminobutyric acid
(GABA) transaminase. It is used as first line treatment for infantile spasm and the drug of choice
for infantile spasm with tuberous sclerosis complex syndrome 1–3 and adjuvant drug in the treatment
of refractory complex partial seizures. In European Union and other countries VGB has been used
since 1990 and in August 2009 USA approved VGB for potential benefit of the drug overweighing
risk of causing permanent concentric visual field defects. VGB treatment is known to cause
peripheral visual field defects and retinal damage in 10-40% of the patients 3.
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In humans, VGB on oral administration of therapeutic dose, is rapidly absorbed with Tmax
of 1.5 h and 60-70% bioavailability. VGB does not bind to plasma proteins and extensively
distributed in the body on oral administration. Over 80% of orally administered VGB is excreted
through urine unmetabolized 4. Only 10% of absorbed VGB enters the brain and responsible for
its therapeutic activity. The various studies carried out in animal models have proven that chronic
administration of VGB in rats leads to ocular toxicity by VGB accumulation in retina, 5,6 which
increases GABA concentrations much higher in retina compared to brain7,8. The high GABA
levels in ocular tissues sensitizes photoreceptors for light leading to retinal degeneration. In vitro
studies have revealed increased GABA levels inhibit retinal uptake of taurine by competitively
inhibiting taurine transporters at retinal pigmental epithelium9. Taurine is an antioxidant which
plays a major role in neuroprotective activities and preclinical studies have reported that taurine
deficiency causes retinal degeneration10–12. VGB treatment in rodent models decreased taurine
plasma and retinal levels and taurine supplementation evidenced a marked decrease in VGB
induced ocular toxicity13,14. In VGB clinical studies plasma taurine level is considered as
biomarker for study of the structure and function of the retina in patients with refractory complex
partial seizures15,16. Further preclinical studies are required to elucidate mechanisms of VGB
induced taurine deficiency and phototoxicity. There is a need to evaluate different approaches to
alleviate the retinal toxicity of this potential drug.
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CHAPTER 2
Intranasal Drug Delivery to Alleviate the Vigabatrin Induced Retinal Toxicity
1. Introduction
On intranasal drug delivery, low molecular weight drugs are directly transported to brain
through olfactory mucosa 17–19. Intranasal drug delivery pathway bypasses blood brain barrier and
blood-cerebrospinal fluid barriers. The main advantage of intranasal route is ease of
administration, patient complaint, low dose requirement, reduces the systemic drug exposure and
associated drug toxicity. The nose to brain delivery of VGB would be a potential approach to
deliver the drug to brain and decrease the systemic exposure, thus associated VGB retinal toxicity.
The accurate estimation of VGB, GABA and taurine concentrations in plasma, brain, and
retina after different routes of administration, gives an insight into the drug efficiency and toxicity
level. A simple, sensitive, and reproducible analytical method is also essential to investigate novel
approaches for alleviating retinal toxicity of VGB in animal models. The estimation of biogenic
amines (GABA and taurine) and VGB in the biological matrices is challenging because they
consist of other endogenous amines, which would compromise the selectivity of the analytical
method. The analysis of these components requires optimization of chromatographic method with
suitable mobile phase composition of appropriate pH and specific column to maintain adequate
resolution by preventing interference of other endogenous amines. Also, these analytes are small
aliphatic molecules and not electroactive nor possess chromophore or fluorophore.
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Hence, for detection of these compounds through simple analytical technique, it is
necessary to derivatize the analytes for introducing chromophore or fluorophore. The derivatized
product should be sensitive and stable for analysis using HPLC. There are previously reported
analytical methods using derivatization techniques with various reagents for quantification of
VGB4,20–24, taurine25 and GABA26–32 in various biological matrices. Also, some analytical methods
include simultaneous estimation of VGB along with GABA 33,34 and taurine along with GABA35,36
in different biological matrices. These currently available methods have low detection limits 20,22,26,
long run times20,29,34, complex derivatization procedures4,23,24,26,30,31 and instable derivatized
products20,22,27,28,34,36. To date, there is no reported analytical technique for simultaneous estimation
of VGB, taurine and GABA. In this study, 2, 3- Naphthalene di carboxaldehyde (NDA)
derivatization method was optimized to increase sensitivity and stability of derivatized product.
In the present study, a simple, cost effective, highly sensitive and reproducible HPLC
method was developed and validated for simultaneous estimation of VGB, GABA and taurine in
human plasma, rat plasma, brain, and retina. The developed HPLC method was applied for
investigation of VGB modulatory effects on GABA and taurine levels in plasma, brain, and retina
of rats after intraperitoneal and intranasal administration. The effect of chitosan and multiblock
copolymer on VGB ex-vivo permeation across bovine olfactory mucosa was assessed. The levels
of VGB, GABA and taurine in plasma, brain, and retina on acute and chronic dose of VGB
(intraperitoneal and intranasal) in Sprague Dawley rats were evaluated. The retinal histology
examination of rats administered with chronic intraperitoneal and intranasal dose of VGB was
performed. The antiepileptic activity on intranasal dose of VGB in pentylenetetrazol induced rat
seizure model was investigated.
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2. Materials and Methods
2.1 Chemicals and reagents
VGB was obtained from Santa Cruz Biotechnology, Inc. USA. GABA, Chitosan medium
molecular weight, pentylenetetrazol, paraformaldehyde, and NDA were purchased from Sigma
Aldrich Inc. USA and taurine standards were purchased from Spectrum chemicals USA. Human
plasma was purchased from Innovative Research Inc. Emsure® Potassium cyanide for analysis was
purchased from EMD Millipore USA. Euthasol® (pentobarbital sodium and phenytoin sodium)
Solution was procured from Virbac USA. HPLC grade solvents acetonitrile, methanol, dibasic
potassium phosphate, glacial acetic acid, O-phosphoric acid, sucrose, and Milli Q water are of
research grade used without further purification.

2.2 Instrumentation and chromatographic conditions
The chromatographic analysis was performed using Waters HPLC system equipped with
Waters 2475 fluorescence detector and Waters 1525 binary pump system operational with an autosampler. Initially the feasibility of different columns (phenyl and C-18), and solvents acetonitrile
and methanol with buffers such as sodium and potassium dihydrogen phosphate (varying pH 3 to
8) along with altered flow rates (in the range of 0.80–1.50 mL/min) was used to achieve an
effective chromatographic resolution of VGB, GABA and taurine. The mobile phase was passed
through the 0.45µm Millipore filter membrane and degassed prior to use. The optimum wavelength
of excitation and emission for analyzing eluent was determined by excitation and emission scan
function in detector.
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2.3 Standard solutions
The 2 mg/mL of VGB, GABA and taurine primary stock solutions were prepared by
dissolving accurately weighed standards in Milli Q water. Working standard solutions were
prepared from the primary stock solutions by subsequent dilutions in Milli Q water. Primary
standards were stored at -20 °C and working standards were prepared regularly and stored at 4 °C
until derivatization and analysis.

2.4 Sample preparation
The brain and retina were isolated from the euthanized male Sprague Dawley rats (7-8
weeks) and immediately snap frozen in dry ice. These tissue samples along with plasma samples
collected from the study and blank animals were stored in -70 ± 5 °C until analysis. The brain and
retinal tissue samples were weighed individually; brain was transferred into 15 mL tarson tubes
and retina to 1.5 mL of micro centrifuge tubes. These tissues were homogenized in two-fold
volume of freshly prepared ice-cold Phosphate Buffered Saline pH 7.4 using ultrasound probe
sonicator. Aliquots of 100µL of rat brain homogenate/ rat retinal homogenate/ rat plasma/ human
plasma was precipitated with 1000µL of ice-cold acetonitrile, and vortexed for 2 min and
centrifuged at 13000 rpm at 4 °C. The aliquots of supernatants were used for derivatization of
amino acids.
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2.5 Optimization of NDA Derivatization
Several analytical studies use O-pthalaldehyde (OPA) as precolumn derivatizing agent for
generating both electroactive and fluorescent active derivatization products of amino acids
(primary amines)20,22,28,29,34,36–38. Researchers have reported on instability of the derivatized
products formed by OPA reagents39. Other agents for derivatizing compounds with primary amine
include

dansyl

chloride,23,24

2-hydroxy

naphthaldehyde,30,31

fluorescamine,21

2,4-

dinitrofluorodinitro benzene26 and NDA31–33. NDA forms relatively stable, sensitive and
fluorescent active 1-cyanobenz (f) isoindole derivatives with primary amines in the presence of
cyanide ions in alkaline conditions40,41. Also, the stable NDA derivatives are more convenient for
the sample handling during HPLC analysis and for HPLC system devoid of online pre-column
derivatization. In this study, samples extracted were derivatized using NDA in presence of cyanide
ions for introducing fluorophore to analytes and internal standard. The derivatization method was
optimized by assessing effect of different concentration of NDA (0.5 to 10 mM), and KCN (0.5 to
10 mM) in different pH (5 to 9.2) of reaction mixture and different reaction time on sensitivity and
stability of formed isoindole derivative. After the reaction time, reaction mixture was quenched
with 20 µL of 1% glacial acetic acid in water, vortex mixed and 10 µl of this mixture was injected
on to HPLC for analysis of derivatized product.

2.6 Method validation
At present there is no existing regulatory guidelines for estimation of endogenous
compound, hence a ‘fit-for-purpose’ approach is suggested to demonstrate the efficiency of the
method. The RP-HPLC method was validated to meet the acceptance criteria of USFDA industrial
guidance for the bioanalytical method validation using surrogate matrix, as biological matrices
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devoid of GABA and Taurine are not readily available. Milli Q water was used as surrogate matrix
and used for validating the HPLC method for simultaneous estimation of VGB, GABA and taurine
in human plasma, rat plasma, brain and retina samples using gabapentin as internal standard (IS).

2.6.1 LLOQ determination
The lower limit of quantification (LLOQ) were calculated based on the standard deviation
of the response and the slope obtained by plotting calibration curves of each analytes (ICH
guideline)42. LLOQ were calculated as 10α/S, where α is the standard deviation of y-intercept and
S is the slope of straight line.

2.6.2 Specificity and selectivity
The samples of the human plasma, rat plasma, brain, and retina from five different lots
were analyzed for evaluating the specificity of the method developed to study the possible
interferences at the retention time of VGB and IS. The specificity for VGB, GABA, taurine and
IS was evaluated by analyzing the 6 injections of Milli Q water to identify the potential
interferences at the retention time of these molecules. The study acceptance criterion was that at
least 80% of total lots must have a peak area less than 5 times of the lower limit of quantification
(LLOQ) peak area in that matrix.
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2.6.3 Calibration curve
The peak-area ratio of VGB, GABA and taurine to that of IS against the actual
concentration of calibration standards in Milli Q water were used for plotting calibration curves.
The concentrations for standard analytes used were 64.6, 129, 258, 646, 1292, 2583, 5166 and
6458 ng/mL for VGB; 51.5, 103, 206, 515, 1030, 2060, 4120 and 5150 ng/mL for GABA and 62.5,
125, 250, 625, 1250, 2500, 5000 and 6250 ng/mL for taurine. The linear regression analysis was
performed with weighting factor of 1/X2, the acceptance criteria for calibration curve should have
a correlation coefficient (r2) of 0.99 or better. The acceptance criteria for each back-calculated
standard concentration were ±15% deviation from the actual concentration except at LLOQ, which
was set at ±20%.

2.6.4 Precision and accuracy
The precision and accuracy (intra and inter day) were determined using six replicates at 4
different levels LLOQ, low, middle, and high-quality control (LQC, MQC and HQC) for each
analyte in three different runs. The quality control (QC) concentration values for VGB were 64.6,
194, 3229, and 5812 ng/mL of LLOQ, LQC, MQC, and HQC, respectively. The QC values for
GABA were 51.5, 155, 2575 and 4635 ng/mL of LLOQ, LQC, MQC, and HQC, respectively. The
QC values for taurine were 62.5, 188, 3125 and 5625 ng/mL of LLOQ, LQC, MQC, and HQC,
respectively. The acceptance criteria for accuracy are ± 15% of the actual concentrations except
for LLOQ where it is ± 20% of actual concentrations. For all quality control samples, a precision
of 15% relative standard deviation (RSD), except for LLOQ it should not exceed 20% of RSD.
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2.6.5 Recovery
The extraction recovery of VGB, GABA, taurine and IS was determined by comparing the
peak-area ratios of the analytes from LQC, MQC, and HQC levels spiked in human plasma, rat
plasma, brain and retinal homogenate (n = 6) with the responses of analytes of LQC, MQC and
HQC concentrations in Milli Q water. The recovery of the GABA and taurine was calculated by
mean background correction and for VGB and IS recovery was calculated with no background
correction.

2.6.6 Stability experiments
The stability of analytes was evaluated in biological matrix (human plasma, rat plasma, rat
brain and retina homogenate) by spiking high QC levels and the samples were evaluated for 8-h
bench top (on ice bath), freeze-thaw (12-h time duration between each of 3 freeze and thaw cycle,
the samples stored at -70 ± 5 °C between cycles) and 60-days long term stability (at -70 ± 5 °C).
The stability of GABA and taurine in biological matrix was calculated by correction for mean
background response (six replicates), which was performed as reported by Richardson et al 43. The
stability samples were processed as described in ‘Sample preparation’ section. The stability of
processed sample/derivatized analytes at LQC and HQC concentrations were subjected to 8 h
bench-top (at room temperature) and in-injector (auto sampler 10 °C) stability. In-injector stability
of processed samples was estimated by injecting at time intervals of 24, 48 and 60 h. All Stability
samples were compared with freshly prepared calibration standard. Samples were considered
stable if assay values were within the acceptable limits of accuracy ± 15% from fresh samples and
precision of 15% RSD.
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2.6.7 Dilution effect
Dilution integrity was assessed to ensure that the biological samples could be diluted with
Milli Q water without having effect on the final concentrations. The biological samples were
spiked with the known high concentrations of VGB (12915 ng/mL), GABA (10300 ng/mL) and
taurine (12500 ng/mL). These samples were diluted 5 times and 10 times with Milli Q water in six
replicates and analyzed. The accuracy of the back calculated samples should be in the range of 85115 % of the actual concentrations and the precision should be within 15 % RSD.

2.7

Vigabatrin thermosensitive gel
On intranasal administration, drugs are extensively cleared due to mucociliary activity. The

mucociliary clearance of a drug can be decreased by employing a mucoadhesive gel to increase
retention of the drug in nasal cavity. Formulating a thermosensitive gel which are liquid at room
temperature and forming gel at nasal cavity temperature would be beneficial to administer the dose
and increase the drug retention at nasal cavity44. VGB is a low molecular weight molecule with
high aqueous solubility. The chitosan and multiblock copolymer (MBCP) are thermosensitive and
mucoadhesive polymers. The chitosan and MBCP (synthesized in house) were used to prepare
gels containing 20% of VGB.

2.7.1 Preparation of Chitosan Hydrogel
Chitosan a naturally occurring polycationic linear polysaccharide polymer, insoluble at
neutral and alkaline pH conditions. At acidic pH, the chitosan solubility increases due to
protonation of amino group. Chitosan with different molecular weight (low < 50 kDa, medium 50150 kDa, high > 150 kDa) are available, the viscosity of gel increases with increase in the
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molecular weight. 20% of vigabatrin was dissolved in 0.1% of glacial acetic acid and different
concentration of medium molecular weight chitosan (0.1, 0.25 and 0.5%) was added at room
temperature and gel formation of these solutions were observed at 32 °C.

2.7.2 Preparation of MBCP Hydrogel
MBCP polymers are novel triblock copolymers synthesized from Pluronic acid® P104 and
di-(ethylene glycol) divinyl ether by employing previously published method by Garipelli et al 45.
The MBCP rheological properties on gelation controls drug release and thus on intranasal
administration forms a in situ depot. The gelation temperature of MBCP polymers are 20 to 40 °C
and degrades at acidic pH. These properties of MBCP gels are ideal for intranasal administration,
as the nasal mucosal temperature is ~34 °C and with a physiological pH of 5.0-6.0 45. The MBCP
polymer at concentrations of 10, 15 and 20% was dispersed in water and the dissolution of MBCP
was facilitated by placing at 2-8 ˚C. Vigabatrin was dissolved separately in water and added to the
polymer dispersions to prepare final concentration of 20% and mixed thoroughly using magnetic
stirrer.

2.8 Permeation of VGB across bovine olfactory mucosa
2.8.1 Preparation of Bovine Olfactory Mucosa
The bovine olfactory mucosa for permeation studies were purchased from Pel-Freez
Biologicals, Arkansas. The excised bovine olfactory mucosa is good model to study the drug
transport across the barrier46. The excised tissue was supplied frozen and tissue was used for the
studies within 24 h of tissue isolation. The tissue was thawed for 30 min, washed with PBS 7.4 pH
and used for permeation studies.
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2.8.2 Permeation Study
The vigabatrin permeation studies across the bovine olfactory mucosa was performed using
vertical Franz diffusion cells. The bovine olfactory mucosa was sandwiched between donor and
receiver chamber of Franz diffusion cell with an active diffusion area of 0.64 cm 2, and the mucosal
surface was exposed to the donor chambers. To ensure the integrity of olfactory mucosa, resistance
across the mucosa was measured using a wave form generator. The bovine olfactory mucosa with
resistance of ≥2.5 KΩ.cm2 was used for permeation studies. To evaluate vigabatrin permeation
from solution and gel across olfactory mucosa, donor compartment was filled with 200 µL of 20%
vigabatrin solution, 200 mg of MBCP and chitosan (0.1%, 0.2% and 0.5%) gel containing 20% of
VGB. The receiver chamber was filled with 5 ml of PBS pH 7.4 and constantly stirred at 600 rpm
with a magnetic stir bar. The temperature was maintained at 37 °C with a circulating water bath.
The 200µL of samples were withdrawn from receiver compartment at different time intervals (0,
0.25, 0.5, 1, 2, 3, 4, 6 and 8 h) and an equal volume of fresh receiver media was replaced. The
above samples were derivatized and subjected to HPLC analysis.

2.9 In-vivo study
Male Sprague-Dawley rats of 7-8 weeks were used for in-vivo studies. The animals were
housed in a room where temperature and humidity were controlled with 12 h light: 12 h dark cycle.
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2.9.1 Retina, brain, and plasma exposure studies
The Animal study was conducted as per study protocol at University of Mississippi, School
of Pharmacy, Mississippi-38677, USA approved by the institutional animal ethical committee. The
dose used in intraperitoneal animals was equivalent to therapeutic human maintenance dose (3
g/day)47, calculated using body surface area conversion factor 48.

2.9.1.1 Acute Study
Acute studies were conducted with 15 Animals and divided into three groups each
containing 5 animals. The first group of animals was used as blank where they were dosed with
normal saline to estimate the basal levels of taurine and GABA. The second group of animals was
dosed at 400 mg/kg dose of VGB by intraperitoneal route of administration. The third group of
animals was dosed at 40 mg/kg dose of VGB by intranasal route of administration. After 2h of
dosing, animals were euthanized using Euthasol® and eyes, brain and blood was harvested. The
plasma was separated from the blood, retina was isolated from the enucleated eye at 4 °C and all
these biological samples were snap frozen immediately after collection and stored at -70 ± 5 °C
until bioanalysis.

2.9.2.1 Chronic Study
Chronic studies were conducted with 15 Animals and divided into three groups each
containing 5 animals. The first group of animals were used as blank where they were dosed with
normal saline for 28 days to estimate the basal levels of taurine and GABA. The second group of
animals was dosed at 400 mg/kg dose of VGB by intraperitoneal route of administration for 28
days. The third group of animals was dosed at 40 mg/kg dose of VGB by intranasal route of
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administration for 28 days. On 28th day, after 2h of dosing animals were euthanized using
Euthasol® and eyes, brain and blood was harvested. The plasma was separated from the blood,
retina was isolated from the enucleated eye at 4 °C and all these biological samples were snap
frozen immediately after collection and stored at -70 ± 5 °C until bioanalysis.
One eye from each animals was used for bioanalysis and other eye was used to examine
the histological changes on chronic intranasal and intraperintoneal dose of VGB. The isolated rat
eyes were fixed with 4% paraformalaldehyde with a small puncture in the cornea and stored in 4
°C for 24 h. After specified time period, the paraformaldehyde was decanted and replaced with
30% sucrose and stored for 2 h at room temperature. The sucrose was washed with PBS after 2 h
and stored at -70 °C and eye samples were shipped for AML laboratories Inc, Florida, USA in dry
ice for cryosectioning. In AML lab, eyes were embeded with optimal cutting temperature (OCT)
compound medium and samples were refrozen. The frozen embeded posterior part of eye were
cryosectioned and sections were mounted on slides. The slides were stained with Heamotoxylin
and Eosin (H&E). The slides were examined under Zeiss microscope, at 20X magnification at The
Univeristy of Mississippi, USA.

2.9.2 Antiepileptic activity of Vigabatrin intranasal dose
The pharmacodynamic studies in epileptic model of SD rats were outsourced and
performed at Invivo Biosciences, Bengaluru, India. The study protocol was approved by the
institutional animal ethical committee of Invivo Biosciences and CPCSEA guidelines for research
in small animals was followed for studies. Pharmacodynamic studies was conducted with 35
animals and divided into 7 groups each containing 5 animals. The first group was used as control,
where they were dosed with normal saline subcutaneously and observed for normal behavior.
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2.9.2.1 Induction of Seizure
The seizure was induced in animals by administering the pentylenetetrazol (PTZ) at dose
of 100 mg/kg subcutaneously 49 and observed for seizure intensity. The Scale for seizure intensity
was observed and scoring 0, 1, 2, 3, 4, and 5 was assigned for signs of motionless, isolated
myoclonic jerks, atypical minimal seizures (some movements observed), minimal seizures (clonic
seizures involving head and forelimb muscles), generalized clonic seizures / tonic phase is absent
/ righting reflexes lost, and complete generalized tonic-clonic seizures with loss of righting reflexes
generalized, respectively.

2.9.2.2 PTZ effect on intraperitoneal and intranasal administration of VGB
Prior to PTZ administration, animals were treated with vigabatrin at different time intervals
and observed for signs of seizures. The second group of animals were dosed with 100 mg/kg of
PTZ subcutaneously and observed for seizure intensity, these animals were used as negative
control. The third group of animals were administered with 900 mg/kg intraperitoneal dose, 6 h
prior to 100 mg/kg of PTZ subcutaneous dose. The fourth, fifth, sixth and seventh group of animals
were administered with 40 mg/kg of intranasal dose, 0.5, 1, 2 and 4 h prior to 100 mg/kg of PTZ
subcutaneous dose, respectively. After PTZ subcutaneous dose, scale for seizure intensity was
observed and scored based on signs.
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2.10

Statistical Analysis
The statistical significance was calculated using GraphPad prism software. The unpaired,

two-tailed t-test analysis was performed for comparing the control group and treated group taurine
and GABA concentrations in rat plasma, rat brain homogenate and retinal samples. The P values
> 0.05 were considered as statistically significant.

3.

Results and Discussion

3.1

Liquid chromatography
The resolution of VGB, GABA and taurine were poor on phenyl and C-8 column. On

Zorbax Eclipse AAA C18 column adequate resolution was observed. The peak tailing was
eliminated by replacing the aqueous mobile phase sodium dihydrogen phosphate with potassium
phosphate dibasic. At pH 6.5 of aqueous mobile phase significantly increased the response of all
three analytes. The resolution and peak shape of analyte was better on use of methanol compared
to acetonitrile. Gabapentin was used as IS as it has similar physicochemical properties with VGB,
GABA and taurine. It is soluble in polar solvents, retained on Zorbax Eclipse AAA column and
elutes with good peak shape and intensity, which will correct the loss of analyte response due to
any variation in instrument. The effective chromatographic separation was obtained using Zorbax
Eclipse AAA column (150 x 4.6mm, 3.5µm; Agilent Technologies) maintained at 25 ± 2 °C. The
resolution of peaks was best achieved with a binary mobile phase system consisting of reservoir
A (methanol) and reservoir B (10mM potassium phosphate dibasic in Milli Q water, pH 6.5
adjusted with phosphoric acid) was run on a gradient profile (0–5.0min, 60% A; 5.0–10.0min 60
to 90% A; 10.0–11.0min, 90% A; 11.0-12.0min, 90 to 60% A and 12.0–15.0min, 60% A) at a flow
rate of 1 mL/min with a run time of 15 min. A good chromatographic resolution was observed
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with a shorter run time compared to previously reported methods for estimation of GABA and
VGB with long run times20,29,34. The optimum response of VGB, GABA, taurine and IS were found
at excitation and emission wavelength of 400nm and 500nm, respectively. These wavelengths
were used to monitor the eluent for method development and validation studies.

3.2

Optimization of NDA Derivatization
By increasing concentration of reagents in reaction mixture, the peak area response of

VGB, GABA and taurine increased. The isoindole products are formed at neutral to basic pH, the
various trials carried out at different pH (6, 6.5, 7, 7.5, 8.0, 8.5 and 9) demonstrated that analyte
peak response of derivatized product was maximum at pH 6.5. The analyte peak area at the
concentration of 0.3 mM of potassium cyanide and 0.2 mM of NDA in dibasic potassium
phosphate buffer at pH 6.5 was optimum. On further increasing concentration of reagents in the
reaction mixture, the interference was increased without increase in the response of VGB, GABA
and taurine. The response of derivatized product increased with reaction time from 2 min to 10
min, after 10 min there was no increase in the response of VGB, GABA and taurine. The sensitive,
stable and linear (at calibration range of vigabatrin, GABA and taurine used for validation)
isoindole derivative was formed with reaction mixture containing 20 µl of sample with primary
amine group, 20 µl of potassium cyanide (4 mM) in water, 20 µl of NDA (2.5 mM) in methanol
and 180 µl of dibasic potassium phosphate buffer (pH 6.5). This modified NDA derivatization
method was used for validation studies by addition of 180 µL of dibasic potassium phosphate
buffer (pH 6.5) containing IS. The NDA derivatization involves a simple procedure at normal room
conditions unlike other derivatization techniques (4-chloro-7-nitrobenzofurazan 4, fluorescamine21,
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dansyl chloride23,24, 2-4-dinitrofluoro dinitrobenzene26 and 2-hydroxy napthaldehyde30,31) which
involves complex procedures like incubating at higher temperatures with longer reaction times.

3.3 Method validation
3.3.1 Specificity & selectivity
The analytical run with the liquid chromatographic conditions described in section 3.1, the
VGB, GABA, taurine and IS were well resolved with total run time of 15 min. There was good
chromatographic specificity with no interference of biological matrices and byproducts of
derivatizing agent were observed. The retention time of taurine, GABA, VGB and IS were 3.8,
4.8, 6.4 and 11.8 min, respectively. No junk peaks were observed at the retention times of analyte
and IS in Milli Q water and biological matrices. Representative chromatograms for the blank (free
of analytes and IS), IS spiked in matrices (Milli Q water, human plasma, rat plasma, brain and
retina), Milli Q water spiked with VGB, GABA and taurine at LLOQ and HQC along with IS and
in-vivo (rat plasma, brain and retina) samples are shown in the Figures 1, 2, 3, 4 and 5, respectively.
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Figure.1 The HPLC Chromatograms of blank (a), blank with IS (b), low limit of quantification
(c) and high-quality control (d).

Figure.2 The HPLC Chromatograms of blank (a), human plasma blank with IS (b), human plasma
with high quality control (c)
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Figure.3 The HPLC Chromatograms of blank (a), blank rat plasma (b) and in vivo plasma sample
at 2hr after VGB administration (c)

Figure.4 The HPLC Chromatograms of blank (a), blank rat brain (b) and in vivo rat brain sample
at 2hr after VGB administration (c)
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Figure.5 The HPLC Chromatograms of blank (a), blank rat retina (b) and in vivo rat retina sample
at 2hr after VGB administration (c)
3.3.2 Recovery
The simple protein precipitation method was preferred over liquid-liquid and solid phase
extraction method for extracting analytes as they are highly polar in nature. The protein
precipitation method is simple, rapid and cost effective compared to solid phase and liquid-liquid
extraction method. The extraction trials were carried out with acidified and alkalinized organic
solvents (acetonitrile and methanol) for enhancing the recovery of analytes from biological
samples. At different concentration level (LQC, MQC and HQC) of each analyte the recovery was
evaluated, and peak area ratio was considered for the calculations. The results (Table 1)
demonstrated the recovery of VGB, GABA and taurine from different matrices were concentration
independent, reliable and reproducible with the use of organic solvent acetonitrile (without
acidification nor alkalinization). The extracted samples were adequately clean as the biological
samples were extracted with higher volume of acetonitrile in ratio of 1:10 (sample: acetonitrile).
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The recovery for the IS at concentration of 2 µg/mL in Milli Q water, human plasma, rat plasma,
rat brain and rat retina were 93.7 ± 2.95, 93.6 ± 9.20, 92.7 ± 7.18, 91.4 ± 5.17 and 91.4 ± 5.17%,
respectively.
Table 1. The recovery of taurine, GABA and vigabatrin at different concentration levels from
different biological matrices and water (n=6)

Biological Matrix

Rat Plasma

Rat Brain

Rat Retina

Human plasma

Stability test

% Recovery (Mean ± SD)
Taurine

GABA

Vigabatrin

LQC

87.8 ± 5.17

91.3 ± 8.14

86.7 ± 2.74

MQC

88.3 ± 6.63

94.9 ± 5.42

93.5 ± 3.75

HQC

91.2 ± 4.92

91.7 ± 4.19

90.7 ± 8.32

LQC

86.2 ± 10.7

90.8 ± 7.17

87.3 ± 3.67

MQC

89.8 ± 4.42

88.1 ± 2.74

86.3 ± 11.1

HQC

93.2 ± 3.29

87.1 ± 5.28

92.4 ± 5.16

LQC

89.5 ± 9.09

85.8 ± 4.30

91.2 ± 7.20

MQC

86.2 ± 10.5

90.7 ± 9.21

86.8 ± 2.27

HQC

90.8 ± 7.79

85.8 ± 7.14

87.2 ± 4.79

LQC

90.1 ± 5.97

93.2 ± 2.99

95.0 ± 6.26

MQC

83.3 ± 8.55

87.4 ± 6.69

85.6 ± 0.82

HQC

88.9 ± 8.17

94.1 ± 9.43

89.7 ± 7.32
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3.3.3 Calibration curve
The standard calibration curve was reproducible over the specified concentration range for
each analyte. A linear response was observed for the range of concentrations 64.6 to 6458 ng/ml
for VGB (r2> 0.994); 51.5 to 5150 ng/ml for GABA (r2> 0.999) and 62.5 to 6250 ng/ml (r2> 0.998)
for taurine. The percentage accuracy observed for the mean of back-calculated concentration of
three linearity’s was within 89.5–107 % for VGB, 88.7–110% for GABA and 95.3–114% for
taurine. The accuracy of the back calculated concentrations of VGB, GABA and taurine linearity’s
were in the range of 85-115 % of the actual concentrations, which met the acceptance criteria. The
linearity range was selected from the LLOQ to 100 times of LLOQ, as the concentration of the
analytes in biological samples depends on the acute or chronic dose of vigabatrin in human and
rats.

3.3.4 Precision & accuracy
The precision and accuracy of intra and inter-day analysis were determined by using
LLOQ, LQC, MQC and HQC levels (six replicates each) on three different days (Table 2 and 3).
The intra-day precisions were in the range of 0.30-5.90, 0.27-4.15, and 0.66-9.15% RSD for
VGB, GABA and taurine, respectively. The inter day precisions were in the range of 1.39-5.30,
2.71-4.08, and 3.53-8.88% RSD for VGB, GABA and taurine, respectively. The accuracy of the
back calculated samples of intra and inter-day were in the range of 85-115 % of the actual
concentrations and the precision was well within 15 % RSD, which met the acceptance
criteria.
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Table 2. The Intra-day precision determination of taurine, GABA and vigabatrin (n=6).
Measured concentration (ng/mL)

control

LLOQ

LQC

MQC

HQC

Taurine

Run
Mean ± SD

RSD

1

63.3 ± 1.65

2.61

2

67.2 ± 1.58

3

GABA
%

Mean ± SD

RSD

101

52.1 ± 1.26

2.48

2.36

107

53.9 ± 1.83

58.8 ± 5.38

9.15

94.0

1

192 ± 4.56

2.37

2

176 ± 9.94

3

Vigabatrin
%

%

Mean ± SD

RSD

101

66.1 ± 1.46

2.21

103

3.40

105

64.6 ± 3.81

5.90

100

52.8 ± 1.35

2.56

103

66.2 ± 3.78

5.71

103

103

144 ± 5.00

3.46

93.4

204 ± 2.34

1.15

106

5.64

94.0

141 ± 2.79

1.97

91.4

201 ± 5.16

2.57

104

160 ± 8.26

5.17

85.5

140 ± 2.61

1.87

90.5

183 ± 0.73

0.40

94.0

1

3054 ± 140

4.59

97.7

2672 ± 25.0

0.94

104

3191 ± 24.2

0.76

99.0

2

2899 ± 50.7

1.75

92.8

2444 ± 42.8

1.75

94.9

3122 ± 56.4

1.81

96.8

3

2852 ± 18.9

0.66

91.3

2618 ± 15.9

0.61

102

3155 ± 9.32

0.30

97.8

1

5138 ± 38.2

0.74

91.3

4590 ± 12.4

0.27

99.0

5258 ± 19.9

0.38

90.6

2

5096 ± 148

2.91

90.6

4349 ± 181

4.15

93.8

5315 ± 192

3.61

91.6

3

4810 ± 82.4

1.71

85.5

4312 ± 52.0

1.21

93.0

5022 ± 38.2

0.76

86.5

Accuracy

SD: Standard Deviation; RSD: Relative Standard Deviation.

Accuracy

Accuracy
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Quality

Table 3. The Inter-day precision determination of Taurine, GABA and Vigabatrin (n=18).
Measured concentration (ng/mL)

Quality
control

Taurine

GABA

Vigabatrin

Mean ± SD

RSD

% Accuracy

Mean ± SD

RSD

% Accuracy

Mean ± SD

RSD

% Accuracy

LLOQ

63.0 ± 4.65

7.38

101

52.9 ± 1.57

2.96

103

65.7 ± 3.01

4.58

102

LQC

176 ± 15.6

8.88

93.9

142 ± 3.84

2.71

91.8

196 ± 10.4

5.30

101

MQC

2935 ± 119

4.07

93.9

2578 ± 105

4.08

100

3156 ± 44.0

1.39

97.9

HQC

5015 ± 177

3.53

89.1

4417 ± 162

3.66

95.3

5198 ± 168

3.22

89.5
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SD: Standard Deviation; RSD: Relative Standard Deviation

3.3.5

Stability
The stability studies were performed to assess stability of VGB, GABA and taurine under

probable sample handling and storage conditions. The stability of analytes in biological matrix
(human plasma, rat plasma, rat brain and rat retina homogenate) was calculated by comparison of
nominal concentration with observed value (after correction for basal levels). The stability results
of analytes in biological matrix for 8-h bench top (ice bath), three freeze–thaw cycles (at -70 ± 5°C
between cycles) and 60-day long term stability (at -70 ± 5 °C) were found to be within ±15% of
the nominal concentrations (Table 4).
The calculated concentrations of processed samples at LQC and HQC level in 8 h benchtop and 48 h in-injector stability test were ±15% of actual concentrations, whereas at 60 h
concentration of the processed samples were <15% of actual concentrations (Table 5). However,
the processed samples started to degrade after 48 h, which was depicted with the sample analyzed
at 60 h. The optimized derivatization method produces stable derivatives of VGB, GABA and
taurine compared to previous reported NDA method for GABA, which demonstrated derivatives
were stable for only 16 h32.
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Table 4. The stability data of taurine, GABA and vigabatrin at HQC concentration in biological matrices (n=6)
Measured concentration (ng/mL)
Matrix

Taurine

Stability test

Mean ± SD

RSD

5472 ± 270

4.93

97.3

4303 ± 268

6.23

Bench Top

5453 ± 180

3.30

96.9

4372 ± 196

Freeze Thaw

5315 ± 186

3.50

94.5

Long Term

5468 ± 241

4.41

0h

5266 ± 280

Bench Top

%

%

92.8

5852 ± 196

3.35

101

4.47

94.3

5776 ± 198

3.43

99.4

4324 ± 304

7.03

93.3

5734 ± 137

2.39

98.7

97.2

4261 ± 159

3.73

91.9

5640 ± 79.4

1.41

97.0

5.32

93.6

4267 ± 165

3.86

92.1

5558 ± 172

3.09

95.6

5372 ± 232

4.33

95.5

4308 ± 117

2.71

93.0

5572 ± 204

3.66

95.9

Freeze Thaw

5230 ± 140

2.68

93.0

4388 ± 116

2.64

94.7

5609 ± 71.2

1.27

96.5

Long Term

5400 ± 75.1

1.39

96.0

4364 ± 131

3.01

94.2

5580 ± 154

2.76

96.0

0h

5286 ± 160

3.04

94.0

4469 ± 161

3.61

96.4

5522 ± 158

2.86

95.0

Bench Top

5297 ± 340

6.41

94.2

4426 ± 157

3.54

95.5

5494 ± 155

2.82

94.5

Freeze Thaw

5304 ± 181

3.41

94.3

4367 ± 163

3.72

94.2

5533 ± 132

2.39

95.2

Long Term

5271 ± 201

3.81

93.7

4429 ± 168

3.80

95.6

5507 ± 106

1.92

94.8

0h

5284 ± 126

2.38

93.9

4412 ± 159

3.60

95.2

5613 ± 178

3.61

96.6

Human

Bench Top

5274 ± 186

3.53

93.8

4384 ± 109

2.49

94.6

5587 ± 146

2.61

96.1

Plasma

Freeze Thaw

5273 ± 155

2.93

93.7

4375 ± 143

3.28

94.4

5380 ± 329

6.09

92.6

Long Term

5211 ± 170

3.26

92.6

3365 ± 149

3.41

94.2

5482 ± 194

3.53

94.3

Rat Retina

0h

%

RSD

Rat Brain

RSD

Vigabatrin
Mean ± SD

Rat Plasma

Mean ± SD

GABA
Accuracy

SD: Standard Deviation; RSD: Relative Standard Deviation.

Accuracy

Accuracy
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Biological

Table 5. The stability data of derivatized product of taurine, GABA and vigabatrin at LQC and HQC concentration (n=6)
Measured concentration (ng/mL)
control

LQC

HQC

Taurine

Time
Mean ± SD

RSD

0h

182 ± 7.57

4.16

Bench top (8 h)

186 ± 7.90

24 h

GABA
%

Mean ± SD

RSD

96.9

143 ± 5.50

3.86

4.25

98.8

147 ± 8.56

184 ± 8.06

4.39

97.8

48 h

177 ± 5.38

3.04

60 h

154 ± 7.55

0h

Vigabatrin
%

%

Mean ± SD

RSD

92.1

188 ± 2.44

1.30

97.1

5.84

94.6

184 ± 10.0

5.47

94.8

144 ± 3.91

2.71

93.0

185 ± 5.03

2.72

95.4

94.0

147 ± 3.87

2.64

94.7

189 ± 7.02

3.70

97.6

4.90

81.9

129 ± 9.45

7.35

83.0

165 ± 9.04

5.48

85.1

5526 ± 113

2.04

98.2

4390 ± 120

2.74

94.7

5436 ± 187

3.44

93.5

Bench top (8 h)

5450 ± 133

2.45

96.9

4415 ± 186

4.22

95.2

5681 ± 112

1.98

97.7

24 h

5468 ± 97.8

1.79

97.2

4443 ± 81.1

1.83

95.9

5472 ± 236

4.31

94.2

48 h

5545 ± 140

2.52

98.6

4426 ± 98.9

2.23

95.5

5495 ± 128

2.33

94.6

60 h

4608 ± 110

2.38

81.9

3814 ± 237

6.22

82.3

4672 ± 198

4.24

80.4

Accuracy

SD: Standard Deviation; RSD: Relative Standard Deviation.

Accuracy

Accuracy
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Quality

3.3.6 Dilution effect
The biological samples were spiked with the known high concentrations of VGB (12915
ng/mL), GABA (10300 ng/mL) and taurine (12500 ng/mL). The biological samples spiked with
higher concentrations and diluted 5 times had accuracy in range of 94.3-107, 97.1-114 and 87.1112% for VGB, GABA and taurine respectively. The samples diluted 10 times had accuracy in
range of 89.3-110, 86.1-104 and 92.1-113% for VGB, GABA and taurine respectively. The
accuracy of the back calculated samples was in the range of 85-115 % of the actual concentrations
and the precision was within 15 % RSD, which met the acceptance criteria. This study
demonstrates that the samples with concentrations greater than the upper limit of quantitation can
be diluted and analyzed to obtain accurate results.

3.4

Vigabatrin thermosensitive gel
The thermosensitive MBCP polymer is solution at 2-8 ˚C and forms a clear gel at room

temperature. These studies have shown 15% of MBCP polymer is optimum to form a vigabatrin
gel, whereas at 10% of polymer was insufficient to form a gel and with 20% MBCP polymer
concentrations, it formed a very thick gel.

3.5

Permeation of VGB across bovine olfactory mucosa
The VGB permeation across bovine olfactory mucosa results are presented in Figure. 6.

There was no difference in permeation of VGB from 20% solution, 0.1, 0.25 and 0.5% chitosan
gels. Whereas, the permeation of VGB from MBCP gels were increased 1.2-fold compared to 20%
VGB solution. The vigabatrin cumulative amount permeated across bovine olfactory mucosa was
in the following order: 20% VGB solution < 0.5% chitosan gel < 0.25% chitosan gel < 0.1%
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chitosan gel < MBCP gel. This study demonstrates MBCP polymers have better VGB permeation
enhancing potential compared to 0.1, 0.25 and 0.5% of chitosan gel.

Cumulative amount permeated (µg/cm2)

10000

Solution
MBCP gel
0.1% Chitosan gel
0.25% Chitosan gel
0.5% Chitosan gel

8000

6000

4000

2000

0
0

2

4
6
8
Time (h)
Figure.6 Permeation of vigabatrin across bovine olfactory mucosa on application of 20% of VGB
solution, 20% of VGB in MBCP, 0.1% chitosan, 0.25% chitosan and 0.5% chitosan gel (mean ±
SD) n=3.

3.6

In-vivo study
The results obtained from the selectivity and sensitivity studies were found to be adequate

for simultaneous quantification of VGB, GABA and taurine in rat plasma, brain and retina
following intraperitoneal and intranasal administration of VGB. 20% VGB in MBCP gels were
used for in vivo acute and chronic intranasal studies.
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3.6.1 Retina, brain and plasma exposure studies
3.6.1.1 Acute Study
The acute study results on VGB intraperitoneal administration of 400 mg/kg, have shown
higher VGB concentrations in retina (19.2 ± 3.65 μg/g) compared to plasma (8.19 ± 1.28 μg/mL)
and brain (1.49 ± 0.45 μg/g). The concentration of VGB in retina was ~2.35 and 12.9 times higher
compared to plasma and brain, respectively. The GABA levels in plasma (27.0 ± 1.22 μg/mL),
brain (73.3 ± 33.2 μg/g) and retina (392 ± 81.7 μg/g) were increased by ~1.47, 2.29 and 7.22 folds,
respectively on intraperitoneal VGB treatment compared to control group. Acute intraperitoneal
studies demonstrated there was no significant difference in the taurine levels in control and VGB
treated animals, which indicates the decrease in taurine levels is not immediate and potentially
chronic administrations might lead to taurine deficiency in retinal tissues. The concentrations of
VGB, GABA and taurine observed in plasma, brain and retinal homogenate on acute study were
shown in Figure 7.
The acute studies after VGB intranasal administration of 40 mg/kg, have shown VGB
concentrations in brain (0.43 ± 0.22 μg/g) and no VGB levels were found in retina and plasma.
There was negligible change in taurine levels in plasma, retinal and brain on intranasal VGB
treatment compared to control group. There was negligible change in GABA levels in plasma and
retinal on intranasal VGB treatment compared to control group. There was 2.1-fold increase in
GABA levels in brain on intranasal VGB treatment compared to control group. Acute studies have
demonstrated on intranasal administration VGB was selectively delivered to brain and there were
below detectable levels of VGB in brain and plasma.
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Figure.7 The concentrations of taurine, GABA and vigabatrin in rat plasma, retina and brain at 2 h after single intraperitoneal and
intranasal dose of vigabatrin in Sprague-Dawley rats (mean ± SD) n=5.

3.6.1.2 Chronic Study
The chronic VGB intraperitoneal administration of 40 mg/kg for 28 days, have shown
higher VGB concentrations in retina (5.54 ± 1.06 μg/g) compared to plasma (2.11 ± 0.34 μg/mL)
and brain (0.37 ± 0.05 μg/g). The concentration of VGB in retina was ~2.62 and 14.9 times higher
compared to plasma and brain, respectively. The GABA levels in plasma (18.0 ± 5.25 μg/mL),
brain (79.0 ± 16.2 μg/g) and retina (179 ± 30.4 μg/g) were increased by ~3.15, 2.33 and 3.70 folds,
respectively on VGB treatment compared to control group. The taurine levels in plasma (11.6 ±
0.71 μg/mL), brain (66.3 ± 11.8 μg/g) and retina (263 ± 22.2 μg/g) were decreased by ~1.54, 2.28
and 2.51 folds, respectively on VGB treatment compared to control group.
The chronic VGB intranasal administration of 40 mg/kg for 28 days, have shown higher
VGB concentrations in brain (0.72 ± 0.21 μg/g) compared to plasma (0.25 ± 0.07 μg/mL) and
retina (0.16 ± 0.10 μg/g). The concentration of VGB in brain was ~2.87 and 4.58 times higher
compared to plasma and retina, respectively. The GABA levels in plasma (9.49 ± 1.00 μg/mL),
brain (63.7 ± 28.0 μg/g) and retina (55.5 ± 6.77 μg/g) were increased by ~1.65, 1.88 and 1.14 folds,
respectively on VGB treatment compared to control group. There was negligible change in taurine
levels in plasma, brain and retina, respectively on intranasal VGB treatment compared to control
group. The concentrations of VGB, GABA and taurine observed in plasma, brain and retinal
homogenate after chronic administration were shown in Figure 8.
The retinal sections of intranasal, intraperitoneal and control group of animals were stained
with H&E. The microscopic images of H&E stained retina are presented in Figure 9, labelled areas
a, b, c and d represents rods and cones, outer nuclear, inner nuclear and ganglion cell layer,
respectively. The negligible change in retinal histology of animals administered with chronic
intranasal VGB compared to control group of animals. The retinal histological sections on chronic
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intraperitoneal administration of VGB, demonstrates the retinal layers were disrupted,
photoreceptors were disorganized and formation of vacuoles in photoreceptor region and inner
retinal layer.
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Figure.8 The concentrations of taurine, GABA and vigabatrin in rat plasma, retina and brain at 2 h after 28th day intraperitoneal and
intranasal (chronic) dose of vigabatrin in Sprague-Dawley rats (mean ± SD) n=5.
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Figure.9 The microscopical image of retinal histology stained with H&E of control (A), intranasal (B) and intraperitoneal (C) group
of Sprague-Dawley rats.

3.6.2

Vigabatrin antiepileptic activity on intranasal administration
The antiepileptic activity of VGB on intranasal and intraperitoneal administration

are presented in Fig 10. The onset time of seizures has been delayed significantly after
intraperitoneal and intranasal administration of VGB compared to PTZ control group. There
were no seizures in control group of animals administered with saline and the seizure intensity
severity score for animals treated with PTZ was 3.4. The seizure intensity of animals treated
with intraperitoneal VGB (900 mg/kg) 6 h pre PTZ dose, intranasal VGB (40 mg/kg) 0.5 h pre
PTZ dose, intranasal VGB (40 mg/kg) 1 h pre PTZ dose, intranasal VGB (40 mg/kg) 2 h pre
PTZ dose and intranasal VGB (40 mg/kg) 4 h pre PTZ dose was decreased by 47.1, 23.5, 17.6,
29.4 and 29.4% compared to PTZ alone treated animals, respectively. The animals treated with
intraperitoneal VGB (900 mg/kg) 6 h pre PTZ dose, intranasal VGB (40 mg/kg) 2 h pre PTZ
dose, and intranasal VGB (40 mg/kg) 4 h pre PTZ dose, shown significant decrease in seizure
intensity compared to PTZ alone treated animals. The animals dosed with 900 mg/kg of VGB
intraperitoneally prdouced maximum antiepiletic activity compared to animals received 40
mg/kg of intranasal VGB dose. However, pharamcodynamic studies demonstrated smaller
intranasal dose produced significant antiepiletic activity and duration of action of intranasal
VGB was upto 4 h.
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Figure.10 The antiepileptic activity; onset of seizures and severity score of convulsions on
intraperitoneal and intranasal dose of VGB.
4.

Conclusion
39

A highly sensitive, specific, and reproducible RP-HPLC method was developed and
validated as per USFDA guidelines for simultaneous estimation of VGB, GABA and taurine. This
study involves simple protein precipitation extraction method with adequate recovery and requires
low sample volume. The NDA method was optimized to produce sensitive and stable derivatized
product, this method of derivatization can be used to produce stable derivatized product of other
primary amine and amino acid with minor modifications. The method was successfully applied to
simultaneously determine the VGB, GABA and taurine concentration in human plasma, rat
plasma, brain and retina. The modulatory effects of VGB on GABA and taurine on intraperitoneal
and intranasal (acute and chronic administration) of VGB were determined. This HPLC method
developed could be applied widely in various clinical and preclinical studies to investigate role of
vigabatrin, taurine and GABA levels on vigabatrin induced ocular toxicity. The MBCP gel
increased the permeation of VGB across the bovine olfactory mucosa. The chronic study
established intranasal administration would be beneficial to increase the VGB levels in brain and
decrease the retinal levels, thus VGB induced retinal toxicity can be alleviated. In vivo
pharmacodynamic studies in epileptic SD rat model has shown intranasal administration of VGB
can be potential approach for management of seizure at lower dose.
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CHAPTER 3
Role of Taurine Transporter in the Retinal Uptake of Vigabatrin
1.

Introduction
Vigabatrin is an anti-epileptic drug of choice for treatment of infantile spasms associated

with tuberous sclerosis complex.50 In treatment of other complex partial seizures, VGB is used as
an adjunct therapy.51 VGB is γ-vinyl-aminobutyric acid, structural analog of inhibitory
neurotransmitter γ-aminobutyric acid. VGB elicits therapeutic activity by suicidal inhibition of
GABA-transaminase thereby preventing degradation of GABA and thus increasing their levels at
synaptic cleft of neurons.50 VGB is a low molecular weight, hydrophilic compound with 60-70%
of oral bioavailability and only 10 % of absorbed VGB crosses the blood brain barrier.52 On
chronic administration of VGB, adults and infants were diagnosed with peripheral atrophy of
retinal nerve fiber layer and decreased electroretinogram amplitudes indicating damage to the
retina.8 Retinal damage causes adverse secondary events leading to bilateral concentric
constriction of the visual field and abnormal visual acuity in 30-40% of patients.3,8 Baseline visual
field testing or electroretinography should be carried out before initiation of treatment and
regularly thereafter to monitor the functions of retina.
VGB is approved by USFDA with black box warning for potential benefit, which
outweigh the risk of causing permanent concentric visual field defects. 53 Preclinical studies of
VGB chronic administration have demonstrated ocular toxicity is caused by VGB accumulation
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in retina.5,6 Accumulated VGB increases GABA concentrations significantly higher in retina
compared to brain5,14 and studies have reported VGB treatment in rodent models decrease taurine
levels in the retina.11,13,14 The preclinical studies demonstrated taurine supplementation decreases
ocular toxicity on VGB administration.12,13,54 Taurine is an antioxidant, plays a major role in
neuroprotective activities and taurine deficiency causes retinal degeneration. 10,55 The mechanism
involved in retinal accumulation of VGB and retinal taurine depletion on VGB chronic
administration is ambiguous.
The uptake of the drug from circulating blood to ocular tissues is via blood aqueous barrier
and the blood retinal barrier. At retinal barrier, lipophilic drugs are transported through ABC
transporters, and amino acid mimetic drugs via solute carrier nutrient transporters. 56 Taurine from
circulating blood is transported into ocular tissues through TauT in RPE and inner BRB. 57 In vitro
(CaCo2 and MDCK) and in vivo rat studies have demonstrated VGB is majorly transported by
proton coupled amino acid transporter-1 (PAT1) across the intestinal barrier. 58–60 Reported studies
have shown PAT1 is involved in cellular influx of zwitterionic amino acids (glycine, proline and
alanine), drugs (D-serine, betaine and D-cycloserine), an essential amino acid taurine and
neurotransmitter GABA, and its analogues.61 In vitro studies in CaCo2, MDCK, and renal cells
have reported taurine transporter (TauT/SLC6a6) is partially involved in uptake of VGB and VGB
inhibits taurine cellular uptake.20
The purpose of present study was to evaluate mechanism involved in VGB transport across
the blood retinal barrier. The in vitro adult retinal pigment epithelium (ARPE-19) cell line studies
and in vivo studies in Sprague Dawley (SD) rats were used to evaluate the role of TauT in VGB
transport into retinal cells. It is crucial to explore the mechanism involved in VGB accumulation
and subsequent taurine depletion to determine the cause of associated retinal toxicity. This study
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will be beneficial to identify and select approaches to prevent or alleviate VGB induced retinal
toxicity.

2.

Materials and methods
ARPE-19 cells and Dulbecco's Modified Eagle Medium (DMEM)-F12 were purchased

from American Type Culture Collection (Manassas, VA, USA). Fetal bovine serum was purchased
from Atlanta Biologics (Flowery Branch, GA, USA). Guanidinoethyl sulfonate was purchased
from Cayman Chemical Company (Ann Arbor, MI, USA). Vigabatrin was purchased from Santa
Cruz Biotechnology Inc. (Dallas, TX, USA). Culture plates and flasks were purchased from
Corning Inc. (Corning, NY, USA). Taurine, GABA and other chemicals were purchased from
Sigma Aldrich (St Louis, MO, USA) and used without further puriﬁcation.

2.1

ARPE-19 Cell culture
ARPE-19 cells used for uptake studies were between passages of 22 and 30. The ARPE-

19 cells were maintained at 37 °C in a humidiﬁed atmosphere of 5% CO 2 and 90% relative
humidity with culture media consisting of D-MEM/F-12 supplemented with 10% fetal bovine
serum, penicillin (100 mg/ml) and streptomycin (100 mg/ml). The medium was replaced every
other day in flask and when the cells reached 80-90% confluence, cells were detached using
Trypsin-EDTA. Detached cells were plated at a density of 0.5 million cells/well in 24-well culture
plates. On attaining cell confluence of 90–95% in 24–well plates, the media was aspirated. These
cells were washed twice with Dulbecco's phosphate-buffered saline (DPBS) and used for cell
uptake studies. All uptake studies were performed by incubating cells with drug containing uptake
buffer62 at 37 °C for 30 min to get maximum uptake. At the end of 30 min incubation period, buffer
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with drug was aspirated and washed with ice cold DPBS three times. After washing, the cells were
precipitated by addition of ice-cold acetonitrile and plates were centrifuged at 4000 RPM to extract
the intracellular drug. The supernatant was aspirated from the plates and subjected to HPLC
analysis.

2.2

ARPE-19 cell uptake studies
The concentration dependent uptake of VGB, GABA and taurine by ARPE-19 cells was

evaluated. The cells were incubated with uptake buffer containing different concentrations of VGB
(50, 40, 30, 20, 10, 5, 2.5, and 1.25 mM), GABA (20, 10, 5, 2.5, 1.25, 0.625, and 0.312 mM), and
taurine (200, 100, 50, 25, 12.5, 6.25, 3.12, and 0.15 µM) for 30 min at 37 °C. At the end of 30 min
incubation period cellular uptake was determined.

2.3

Effect of osmolarity and pH on uptake of VGB
The effect of osmolarity on VGB and taurine uptake were studied. The cells were

preincubated for 16 h with hyperosmolar (400 mOsm) uptake buffer containing 50 mM sodium
chloride.63 After preincubation, hyperosmolar uptake buffer was aspirated and washed the cells
with DPBS twice. These cells were incubated with uptake buffer containing VGB (50 mM) and
taurine (0.2 mM) for 30 min at 37 °C. The effect of pH on uptake of VGB was evaluated by
incubating the cells with uptake buffer of pH 5.5, 6.5 and 7.5 containing VGB (50 mM) and taurine
(0.2 mM) for 30 min at 37 °C. At the end of 30 min incubation period cellular uptake was
determined.
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2.4

Effect of Guanidinoethyl sulfonate on uptake of VGB
The study was performed to identify the transporter involved in ARPE-19 cellular uptake

of VGB. The cells were preincubated with uptake buffer containing different concentrations (50,
40, 30, 20, 10, 5 and 2.5 mM) of TauT inhibitor guanidinoethyl sulfonate (GES) 64,65 for 30 min.
To the preincubated cells VGB (50 mM), GABA (20mM), and taurine (200 µM) was added and
cells were incubated for 30 min at 37 °C. At the end of 30 min incubation period cellular uptake
was determined.

2.5

Competitive inhibition of cellular uptake of TauT substrates in ARPE-19 cells
To study VGB interaction with TauT, the uptake experiments were conducted in presence

of TauT endogenous substrates. The cells were preincubated with uptake buffer containing VGB,
GABA and taurine for 30 min. To the cells preincubated with VGB (10 mM), different
concentrations of GABA (20, 10, 5, 2.5, 1.25, 0.625, and 0.312 mM), and taurine (200, 100, 50,
25, 12.5, 6.25, 3.12, and 0.15 µM) were added and incubated for 30 min to study the effect of VGB
on uptake of GABA and taurine. To the cells preincubated with GABA (2 mM), different
concentrations of VGB (50, 40, 30, 20, 10, 5, 2.5, and 1.25 mM), and taurine (200, 100, 50, 25,
12.5, 6.25, 3.12, and 0.15 µM) were added and incubated for 30 min to study the effect of GABA
on uptake of VGB and taurine. To the cells preincubated with taurine (50 µM), different
concentrations of VGB (50, 40, 30, 20, 10, 5, 2.5, and 1.25 mM), and GABA (20, 10, 5, 2.5, 1.25,
0.625, and 0.312 mM) were added and incubated for 30 min to study the effect of taurine on uptake
of VGB and GABA. At the end of 30 min incubation period cellular uptake was determined.
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2.6

Animal Studies
The Animal study was conducted as per study protocol approved by the institutional animal

ethical committee at University of Mississippi, School of Pharmacy, Mississippi- 38677, USA.
Twenty-four male SD rats of age 7–8 weeks were procured from Envigo and used for assessing
the effect of chronic administration of GES and taurine on retinal levels of VGB. The animals were
housed in a room, where temperature and humidity were controlled with 12 h light:12 h dark cycle.
Animals were divided into four groups each containing 6 animals. The first group of animals were
untreated, where they were dosed with normal saline to estimate the basal levels of taurine in
retina. The second group of animals was dosed with normal saline for 10 days intravenously and
on 10th day animals were dosed with 400 mg/kg of VGB by intraperitoneal route. The third group
of animals were dosed with GES at 1 mg/kg intravenously for 10 days and on 10 th day animals
were dosed with 400 mg/kg of VGB by intraperitoneal route. The fourth group of animals were
dosed with taurine at 100 mg/kg orally for 10 days and on 10 th day animals were dosed with 400
mg/kg of VGB by intraperitoneal route. On 10th day, after 2 h of dosing animals of all groups were
euthanized using Euthasol®, and eyes are enucleated and snap frozen. Retina was isolated at 4 °C
and homogenized using phosphate buffered saline and stored at -70 ± 5 °C until bioanalysis.

2.7

Sample Preparation
The samples are analyzed simultaneously for VGB, GABA and taurine using method

described in Chapter-2. The samples for analysis were derivatized using 2, 3‑Naphthalene
dicarboxaldehyde (NDA) derivatization method. Briefly, 20 µL of supernatant of in vitro uptake
study samples/retinal homogenate were added to derivatizing agent containing 20 μL of potassium
cyanide (4 mM) in water, 20 μL of NDA (2.5 mM) in methanol and 180 μL of dibasic potassium
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phosphate buﬀer (pH 6.5). The reaction mixture was incubated at room temperature for 10 min
and 20 µL of 1% glacial acetic acid was added to terminate the reaction. Above reaction mixture
was vortexed and 10 µL of these samples were injected into HPLC.

2.8

HPLC Analysis
Waters HPLC system equipped with Waters 2475 fluorescence detector and Waters 1525

binary pump system was used for analysis. Zorbax Eclipse AAA column (150×4.6 mm, 3.5 μm;
Agilent Technologies) was used as stationary phase, which was maintained at 25 ± 2 °C. The
mobile phase consisted of methanol (70%): 10 mM dibasic potassium phosphate at pH 6.5 (30%)
with flow rate of 1 ml/min. The VGB, GABA and taurine were analyzed using fluorescence
detector at excitation and emission wavelength of 400 nm and 500 nm, respectively.

2.9

Statistical analysis
All study data are expressed as mean ± S.D of sextuplicate values. The unpaired student t-

test or one-way analysis of variance (ANOVA) were used for statistical comparisons of mean
values. The data with P value <0.05 were considered as statistically significant. The Km and Vmax
of substrates and IC50 values of inhibitors were calculated using GraphPad Prism version 6.0.
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3.

Results

3.1

ARPE-19 cell uptake studies
Uptake of VGB, GABA and taurine into ARPE-19 cells was evaluated by quantifying

intracellular drug levels after 30 min incubation. ARPE-19 cells are outer blood retinal barrier cells
and the entry of drug into cells is guarded by ABC and SLC transporters. The reported studies
have proved that GABA and taurine uptake into retinal cells are TauT mediated. 66–69 In this study,
known substrates GABA and Taurine for TauT are used as positive control for uptake studies.
ARPE-19 cell line studies demonstrate the transport of the VGB, GABA and taurine into
cells are concentration dependent. The cellular uptake study curve Figure 1. (A, B and C) displays
saturable kinetics indicating VGB, GABA and taurine transport into cells are carrier mediated. The
Km value of VGB, GABA and taurine were calculated using Michaelis-Menten equation for
translocation of these molecules into ARPE-19 cells and the Km value of VGB, GABA and taurine
was found to be 13.1 mM, 1.92 mM and 58.72 µM, respectively.
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Figure 1. The ARPE-19 cell uptake of (A) VGB, (B) GABA and (C) Taurine at different
concentrations (mean ± SD) n=6.

49

3.2

Involvement of TauT in VGB uptake by ARPE-19 cells
The expression of TauT in ARPE-19 cells has been demonstrated in previous studies by

immunohistochemical experiments,70 by ARPE-19 TauT mRNA quantification63 and in-vitro
experiments were conducted to demonstrate presence of high affinity transport system in ARPE19 cells.68 TauT is Na+-Cl- dependent transporter, their expression and/or functionality is
dependent on the osmolarity, pH conditions, and presence of TauT substrates or inhibitors. 57,63,71
In present study taurine was used as positive control as it has higher affinity to TauT and are
specifically transported into human RPE cells by TauT. 72

3.2.1 Effect of osmolarity and pH on uptake of VGB
To evaluate TauT (Na+-Cl- dependent transporter) role in VGB uptake, the cells were
incubated in different pH and osmolarity conditions. The results in figure 2 (A and B) depicts
uptake of VGB and taurine under hyperosmolar condition was increased significantly by 3.6 and
3.2-fold, respectively compared to iso-osmolar conditions at pH 7.4 (P<0.001, n=6). The results
in figure 2C depicts VGB uptake into cells was decreased significantly by 5.8 and 2.6-fold at pH
5.5 and 6.5 compared to pH 7.4, respectively (P<0.001, n=6). The results in figure 2D depicts
taurine uptake into cells was decreased significantly by 3.4 and 1.2-fold at pH 5.5 and 6.5
compared to pH 7.4, respectively (P<0.001, n=6). The TauT shows maximum activity at
hyperosmolar condition and pH 7.4. At lower pH, VGB and taurine transport across the cell barrier
is reduced.33
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Figure 2. The effect of osmolarity and pH on uptake of (A, C) VGB and (B, D) taurine by ARPE19 cells. (* p < 0.05, ** p < 0.01, and *** p < 0.001) (mean ± SD) n=6.
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3.2.2 Effect of Guanidinoethyl sulfonate on uptake of VGB
Preincubation of cells with GES, a TauT inhibitor decreased the cellular uptake of VGB,
GABA and taurine (figure 3). The IC50 value of GES was 2.62, 3.48 and 7.49 mM for ARPE-19
cell uptake of VGB, GABA and taurine, respectively. Study results confirms TauT is involved in
VGB uptake across ARPE-19 cell barrier.

Figure 3. The effect of GES on uptake of VGB, GABA and taurine by ARPE-19 cells (mean ±
SD) n=
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3.2.3 Competitive inhibition of cellular uptake of TauT substrates in ARPE-19 cells
Competitive inhibition of ARPE-19 cell uptake of VGB, GABA and taurine were analyzed
using Lineweaver-Burk plot. The Km of vigabatrin 13 mM was significantly increased by 4.86
and 2.10-fold in presence of taurine and GABA, respectively (P<0.01, n=6). The Km of taurine 60
µM was significantly increased by 4.31 and 3.43-fold in presence of GABA and VGB, respectively
(P<0.01, n=6). The Km of GABA at 1.89 mM was significantly increased by 3.65 and 1.79-fold
in presence of taurine and VGB, respectively (P<0.01, n=6). There were no significant changes in
Vmax of VGB, taurine and GABA in presence of each other. The Lineweaver-Burk Plot for uptake
of VGB, taurine and GABA in presence of taurine and GABA, GABA and VGB, and taurine and
VGB are presented in figure 4. These results indicate VGB is substrate of TauT and VGB competes
with GABA, and taurine for ARPE-19 cellular uptake.
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Figure 4. Competitive uptake inhibition (Lineweaver-Burk plot) of VGB, GABA and taurine in
ARPE-19 cells. Effect of VGB on uptake of (A) GABA and (B) taurine. Effect of GABA on uptake
of (C) VGB and (D) taurine. Effect of Taurine on uptake of (E) VGB and (F) GABA by ARPE-19
cells (mean ± SD) n=6.
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3.3

Animal Studies
In vivo studies in SD rats were performed to confirm TauT involvement in retinal exposure

of VGB. On chronic administration of GES at 1 mg/kg, retinal levels of VGB (figure 5) decreased
significantly by 1.5-fold (P<0.001, n=6) compared to animals administered with similar dose of
VGB alone. On chronic administration of taurine at 100 mg/kg, retinal levels of VGB (figure 5)
decreased significantly by 1.3-fold (P<0.01, n=6) compared to animals administered with single
similar dose of VGB alone. This study results prove TauT plays a pivotal role in retinal exposure
of VGB.

Figure 5. The effect of chronic administration of taurine and GES on retinal exposure of VGB on
single dose of VGB 400 mg/kg body weight. (* p < 0.05, ** p < 0.01, and *** p < 0.001) (mean
± SD) n=6.
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4.

Discussion
Blood retinal barrier is composed of retinal pigment epithelium (RPE), these cells form

tight junctions at lateral surfaces of retina and prevents the inner retinal layer from systemic
exposure. RPE plays a major role in supplying nutrients to retina and maintaining ocular
homeostasis.73 ARPE-19 is a spontaneously arising retinal pigment epithelium cell line derived
from eyes of a male 19-year-old human. RPE-19 cell lines express variety of ABC and SLC
transporters and hence used as a potential in vitro model for assessing drug and nutrient transport
across blood retinal barrier.67,74,75 SLC6A6/TauT is a Na+-Cl- dependent high affinity taurine
transporter expressed in ARPE-19 cells, which is involved in transport of taurine. 72 Taurine is an
abundant amino acid present in retina and plays a crucial role in osmoregulation and
neuromodulator effect.55 TauT is expressed in brain, retina, liver, intestine and renal tissues.
Though TauT is expressed in different tissues, its activity is greater at BRB and transportability of
taurine across BRB is 30 times greater than blood brain barrier. 57
Previous in vitro studies using CaCo2 and MDCK studies have proven VGB transport
across the cells are mediated by SLC (PAT-1 and partially by TauT). 76 In the present study, uptake
of VGB into ARPE-19 cell was saturable and concentration dependent indicating carrier mediated
process was involved in VGB translocation into retinal cells. GABA and taurine are known
substrates of TauT in retinal cells and the Km values in present APRE-19 cell line studies are 1.92
mM and 58.72 µM, respectively.
In vitro taurine uptake was inhibited by 30 mM of VGB in MDCK and Caco-2 cell lines,
which indicates interaction of VGB with TauT.77 We hypothesized that VGB transport across the
retinal barrier might also involve TauT. In hyperosmolar conditions taurine levels increase in RPE
cells to maintain cell volume homeostasis.78 In vitro studies have shown ARPE-19 cells cultured
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in hyperosmolar conditions increased TauT activity, which maximized the taurine uptake. 63 In
present study, the effect of hyperosmolarity on VGB uptake into ARPE-19 cells was assessed.
VGB uptake was significantly increased compared to iso-osmolar condition. At lower pH, TauT
activity has been reported to be lesser than physiological pH conditions. 71 In agreement with the
earlier report, the present study demonstrated the decreased uptake of VGB at pH 5.5 in ARPE-19
cells. Whereas, at physiological pH 7.4 the cell uptake of VGB was concentration dependent and
saturable. These studies indicate the involvement of TauT in VGB uptake into ARPE-19 cells.
Studies reported have shown GABA and GABA mimetics competitively inhibits taurine uptake in
retinal and other cell lines,76 indicating interaction of TauT in transport of GABA and GABA
mimetics. The competitive inhibition study results of GABA and taurine was in accordance with
the previous published reports in retinal cell lines, where GABA and taurine were competitively
inhibiting the uptake of each other into cells.9 The kinetic analysis using Lineweaver-Burk plot
demonstrated a increase in the Km of VGB in presence of GABA and taurine with unchanged
Vmax, which proves the competitive inhibition in presence of TauT substrates in ARPE-19 cells.
The competitive inhibition of VGB, GABA and taurine indicate increased levels of VGB at site of
retinal barrier will decrease the uptake of taurine, and vice versa.
On chronic administration of GES in rats, GES produces taurine depletion in retina and
other tissues by interacting with its carrier-mediated transport.

64,65,79

In vitro and In vivo study

results demonstrated VGB uptake into ARPE-19 cells (figure 3) and retinal tissues (figure 5) was
inhibited by GES, indicating the involvement of TauT in VGB retinal uptake. On chronic
administration of taurine in rats decreased the levels of VGB into retinal tissues (figure 5),
demonstrating competitive inhibition of VGB retinal uptake by taurine. Previous studies have
reported chronic supplementation of taurine decreased the VGB related ocular toxicity in rats. 11
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Apparently, these findings from in vitro and in vivo studies indicate the VGB transport and
accumulation into retina is predominantly governed by TauT. The subsequent retinal toxicity is
associated with taurine depletion from retina on chronic administration of VGB 6,13,14 is due to
competitive inhibition of taurine retinal uptake by VGB. Further preclinical studies are required to
optimize the dose and duration of taurine supplementation to alleviate the VGB induced retinal
toxicity.

5.

Conclusion
In vitro ARPE-19 cell line and in vivo rat studies demonstrate VGB uptake into retinal cells

involves TauT. The TauT mediated uptake of VGB was modulated by GABA, taurine and TauT
inhibitor. These studies explain mechanism involved in VGB accumulation and subsequent retinal
toxicity. The supplementation of taurine will alleviate VGB treatment associated visual
complications in infantile spasms, however further preclinical and clinical studies are required to
optimize the taurine dosage regimen.
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CHAPTER 4
Cytoprotective Effects of Silymarin on Antiepileptic Drug Induced Retinal Toxicity

1.

Introduction
Most of the antiepileptic drugs at therapeutic dose cause visual disturbances and retinal

neuronal toxicity on chronic treatment80,81. The mechanism of antiepileptic drugs involves
modulation of GABA and glutaminergic transmission. An increase in non-synaptic GABA
responses and glutamate induced oxidative stress in retinal neuronal tissue produces visual
complications and retinal electrophysiological changes. Anti-epileptic drugs, modulating
GABAergic system such as vigabatrin, gabapentin, topiramate and tiagabine were selected and all
these produces clinical adverse ocular events. Antiepileptic drugs toxicity in retinal cell lines were
studied.
Neuroprotective and antioxidant adjuvants would be beneficial for suppressing
antiepileptic drug induced retinal toxicity. The extract of Silybum marianum comprises of
flavonolignan and flavanol mixtures collectively termed as silymarin 82. Taxifolin, silychristin,
silydianin, silybin and isosilybin are the major constituents of extract. Silymarin is used traditional
as antidote for amatoxin poisoning and to treat chronic liver disorders (hepatitis and cirrhosis).
Silymarin constituents are extensively studied (both in vitro and in vivo) to evaluate its potential
in treatment or management of cancer, hypocholesterolemia and chronic liver diseases 83. The
therapeutic activity of silymarin is attributed to their antioxidant activity 84. Silymarin extracts are
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one of the most widely used herbal supplements in United States, as no severe adverse events
reported on their consumption.
The objective of present study was to evaluate the effects of antiepileptic drug VGB,
gabapentin, topiramate and tiagabine on retinal neuronal and retinal epithelial cells. To investigate
the potential cytoprotective effect of silymarin and taurine on antiepileptic drug induced retinal
toxicity and to establish the probable mechanism of silymarin cytoprotective effect.

2.

Methods and Materials
ARPE-19 cells and Dulbecco's Modified Eagle Medium (DMEM)-F12 were purchased

from American Type Culture Collection (USA). R28 cells were purchased from Kerafast, Inc
(USA). Bovine calf serum was purchased from GE Healthcare life sciences (USA). Fetal bovine
serum (FBS) was purchased from Atlanta Biologics (USA). JC-1 assay kit and Hoechst stain were
purchased from Cayman chemical. Viagabtrin and gabapentin was purchased from Santa Cruz
Biotech. (USA). Topiramate, hydrogen pyroxide, tiagabine, MTT reagent, Silybin (Silibinin),
Silymarin extract and DCHDA reagent were purchased from Sigma-Aldrich (USA). Isosilybin and
silychristin was purchased from Tractus Company Limited (England). Silydianin was purchased
from ChromaDex Inc. (USA). Taxifolin was purchased from Enzo Life Sciences Inc. (USA). DNA
tunnel and LDH assay kit were purchased from Promega Inc. (USA). Culture plates and flasks
were obtained from Costar (Corning, USA). All other chemicals were purchased from Sigma
Chemical Company (USA) and used without further puriﬁcation.
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2.1

Retinal Cell culture
Retinal cell toxicity of antiepileptic drugs was determined using adult retinal pigmental

epithelial (ARPE-19) cells and retinal neuronal (R28) cells.

2.1.1 ARPE-19 cell culture
ARPE-19 cells are adult retinal pigmental epithelial cells. The cells between passages of
22 and 30 were used for uptake studies. The ARPE-19 cells were maintained at 37 °C in a
humidiﬁed atmosphere of 5% CO2 and 90% relative humidity with culture media that consisted of
D-MEM/F-12 supplemented with 10% fetal bovine serum, penicillin (100 µg/mL) and
streptomycin (100 µg/mL).

2.1.2 R28 cell culture
R28 cells are immortal postnatal day 6 rat retinal neuronal cells with characteristics of glial
and neuronal cell markers. R28 cells were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% bovine calf serum, 3% sodium bicarbonate solution (7.5% stock solution),
1% MEM non-essential amino acids 10X, 1% MEM vitamins 10X, 1% L-glutamine (200mM stock
solution) with gentamicin (100 µg/mL) and incubated at 37 o C in 5% CO2.
In both cell culture studies, media was replaced every other day in flask and when the cells
reached 80-90% confluence, cells were detached using Trypsin-EDTA. Detached cells were plated
at a density of 0.1 million cells/well on 96-well culture plates and used for studies.
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2.2

Cell Viability Assay
Cell viability assays were performed by exposing each well of ARPE-19 and R28 cells to

different concentrations of VGB (40, 20, 10, 5, 2.5, 1 and 0.5 mM), gabapentin (40, 20, 10, 5, 2.5,
1 and 0.5 mM), topiramate (50, 25, 12.5, 6.25, 3.62, 1.81 and 0.9 µM), tiagabine (10, 5, 2.5, 1, 0.5
and 0.25 mM) and hydrogen peroxide (1, 0.5, 0.25, 0.1, 0.05 and 0.025 mM) in six replicates to
determine the IC50 (concentration required to kill 50% of total cells incubated). After incubation
period of 24 h, cell viability in each well was quantified by using 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) reagent. 20 µL of MTT reagent solution (5 mg/mL) was
added to each well and incubated at 37 o C for 4h. After incubation period, the MTT solution was
removed and the purple formazan crystals formed were dissolved by adding 100 µL of DMSO in
each well. Absorbance was determined at 570 nm using a Microplate Reader.

2.3

Nuclear condensation and DNA fragmentation assay
Nuclear condensation and DNA fragmentation are the morphological and biochemical are

characteristics of apoptosis. The effect of VGB and gabapentin exposure on nuclear condensation
of R28 and ARPE-19 cells was evaluated using Hoechst 33258 stain. On R28 and ARPE-19 cells
attaining 80-90% confluence, the R28 and ARPE-19 cells were exposed to vigabatrin and
gabapentin at 20mM concentration in serum free media for 24 h at 37 °C. After incubation period
the media was aspirated and washed cells with PBS. The cells were treated with Hoechst’s stain
and incubated in dark for 10 min at room temperature. The staining solution was removed, and
cells were washed with PBS two times. The bright field and fluorescence microscopy images using
DAPI filter were captured using Olympus microscope equipped with camera.
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The effect of vigabatrin and gabapentin exposure on DNA of R28 and ARPE cells were
detected using Dead End™ Fluorometric TUNEL System. The ARPE-19 and R28 cells were
exposed to different concentrations of VBG (20, 10, 5, 2.5, 1 and 0.5 mM) and gabapentin (20, 10,
5, 2.5, 1 and 0.5 mM) for 24 h at 37 o C in 5% CO2 in six replicates to determine the concentration
dependent effect on DNA fragmentation. After incubation period, the cells were washed with PBS
two times and processed to detect DNA fragmentation induced by vigabatrin and gabapentin. The
DNA fragmentation in cells were detected by employing the method described by Promega (Dead
End™ Fluorometric TUNEL System kit supplier). Briefly, the cells were fixed in 96 well plate
using freshly prepared 4% methanol free formaldehyde solution in PBS for 25 min at 4 o C. The
cells were washed with PBS three times and cells were permeabilized by treating with 0.2%
Triton® X-100 solution in PBS for 5 min. These cells were washed with PBS three times and
incubated for 10 min at room temperature with equilibration buffer. The Terminal
Deoxynucleotidyl Transferase, recombinant enzyme (rTdT) was added to each well and incubated
for 60 min at 37 o C. The reaction was terminated by addition of 2X SSC solution and incubating
for 15 min at room temperature. The cells were washed with PBS for 3 times to remove the
unincorporated fluroscein-12-dUTP and cells were stained with Hoechst’s stain as mentioned
above to visualize the nuclei. The cells were visualized to detect the fragmented DNA with
Olympus fluorescence microscope using DAPI and GFP filters equipped with camera.
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2.4

Mitochondrial membrane potential assay
Mitochondrial membrane integrity is an important parameter of mitochondrial function and

indicates the cell health. 5,5’,6,6’-tetrachloro-1,1’,3,3’-tertraethylbenzimi-dazolylcarbocyanine
iodide (JC-1) is a cytofluorimetric lipophilic cationic dye used to evaluate the difference in
mitochondrial membrane potential. JC-1 enters the mitochondria of healthy cells and forms
aggregates with emission of red fluorescence. In unhealthy cells, JC-1 remain in monomeric form
with emission of green fluorescence. This study was performed to evaluate the early apoptosis
induced by vigabatrin and gabapentin using JC-1 mitochondrial membrane potential detection kit.
The ARPE-19 and R28 cells were exposed to different concentrations of VBG (50, 25, 12.5, 6.25,
3.62, 1.81 and 0.9 mM) and gabapentin (50, 25, 12.5, 6.25, 3.62, 1.81 and 0.9 mM) in six replicates
to determine the concentration dependent effect on mitochondrial membrane potential of cells.
After incubation period of 24 h, the cells were washed with DPBS two times and treated with JC1 reagent for 30 min at 37o C in 5% CO2. Cells were washed and measured on a fluorescence multi
well plate reader at two different set of wavelengths at excitation/emission 540/570 nm (red
fluorescence for healthy cells) and 485/535 nm (green fluorescence for unhealthy/apoptotic cells).
The cells were pretreated with silymarin and taurine, to study their effect on VGB and gabapentin
induced mitochondrial membrane potential changes.

2.5

Detection of Reactive oxygen species generation
The ROS generation by antiepileptics and hydrogen peroxide was estimated in ARPE19

and R-28 cells by using the fluorescent dye 2,7- dichlorodihydrofluorescein diacetate (DCFDA).
DCFDA hydrolyses in presence of reactive oxygen species and produces fluorescent
dichlorodihydrofluorescein DCF. The amount of DCF produced is proportional to the amount of
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ROS present. On cells attaining the 80-90% confluence, cells were washed with Dulbecco’s
phosphate buffered saline (DPBS) and incubated with 0.5 mM of DCFDA in DPBS for 1 h at 37
°C. R28 Cells were washed with DPBS and incubated with 25 mM VGB, 15 mM gabapentin and
0.1 hydrogen peroxide in serum free media for 24 h at 37°C. ARPE-19 Cells were washed with
DPBS and incubated with 25 mM VGB, 50 mM gabapentin and 0.3 hydrogen peroxide in serum
free media for 24 h at 37°C. Cells were washed and measured on a fluorescence multi well plate
reader setting the wavelength at excitation 485 nm, and emission 530 nm. The effect of silymarin
and taurine on ROS generated by VBG, gabapentin and hydrogen peroxide were evaluated. The
ARPE-19 and R28 cells (pretreated with DCFDA for 60 min) were treated to VGB, gabapentin
and hydrogen peroxide in presence of taxifolin (100 µM), silychrsitin (100 µM), silydianin (100
µM), silybin (100 µM), isosilybin (100 µM) and taurine (10 mM).

2.6

Cytoprotective effect
Cytoprotective effect of silymarin and taurine were evaluated by exposing each well of

ARPE and R28 cells to different concentrations of taxifolin, silychristin, silydianin, silybin,
isosilybin (200, 100, 50, 25, 10 and 5 µM) and taurine (20, 10, 5, 2.5, 1 and 0.5 mM) along with
IC50 concentrations of VGB, gabapentin and hydrogen peroxide in six replicates. After incubation
period of 24 h, cell viability in each well was quantified by using MTT reagent and absorbance
was determined at 570 nm using a Microplate Reader.
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2.7

Statistical Analysis
Data from in vitro cell line studies were subjected to statistical analysis by ANOVA

(Tukey’s Multiple Comparison Test for comparing between pairs of data) using the GraphPad
Prism version 3.00 statistics program (GraphPad Software, Inc., San Diego, CA). P values less
than 0.05 were considered statistically significant.

3.

Results and discussion

3.1

Cell Viability Assay
The viability of R28 and ARPE-19 cells on exposure to VGB, gabapentin, tiagabine,

topiramate and hydrogen peroxide (positive control) was assessed using the MTT reagent solution.
The percentage viability of R28 cells after 24 h exposure of VGB (40 mM), gabapentin (40 mM),
tiagabine (50 µM), topiramate (10 mM) and hydrogen peroxide (0.25 mM) was 48.0, 4.04, 73.7,
79.7 and 2.05 %, respectively (Figure 1). At 24 h of exposure to VGB, gabapentin and hydrogen
peroxide the viability of R28 cells were decreased with increasing concentrations and the IC 50 was
37.5, 13.7 and 0.10 mM, respectively.
The percentage viability of ARPE-19 cell on 24 h exposure of VGB (50 mM), gabapentin
(50 mM), tiagabine (50 µM), topiramate (10 mM) and hydrogen peroxide (0.5 mM) was 47.7,
67.9, 73.7, 80.2 and 9.49 %, respectively (Figure 2). At 24 h of exposure to VGB, gabapentin and
hydrogen peroxide the viability of ARPE-19 cells were decreased with increasing concentrations
and the IC50 was 27.5, 73.5 and 0.31 mM, respectively. The VGB, gabapentin was found to be
toxic for both cell lines in concentration dependent manner compared to topiramate and tiagabine.
VGB and gabapentin were further studied to determine mechanism of retinal cell toxicity.
a
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Figure 1. Effect of varying concentrations of vigabatrin(A), gabapentin(A), tiagabine(B), topiramate(C) and hydrogen peroxide(D)
exposure on viability of R28 cells (mean ± SD) n=6.
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Figure 2. Effect of varying concentrations of vigabatrin(A), gabapentin(A), tiagabine(B), topiramate(C) and hydrogen peroxide(D)
exposure on viability of ARPE-19 cells (mean ± SD) n=6.

3.2

Nuclear condensation and DNA fragmentation assay
Apoptosis is programmed cell death with biochemical features including loss of membrane

asymmetry, membrane blebbing, increase in caspase activity, decrease in mitochondrial membrane
potential, chromosome condensation (pyknosis), DNA fragmentation (karyohexis), DNA
laddering and the eventual engulfment of the cell by phagosomes 85.
The condensation of cell nuclei was captured by fluorescence microscope, blue fluorescent
Hoechst 33258 is a cell permeable nucleic acid dye used to identify condensed nuclei by staining 86.
The morphological observation in the cell nuclei of R28 and ARPE-19 cells after 24 h treatment
with or without vigabatrin and gabapentin showed significant morphological alterations when
compared to untreated control. ARPE-19 and R28 cells nuclear condensation was showed in figure
3 and 4, respectively. As observed in figures 3 A and B, the control or untreated cells appeared to
be intact oval shape and the nuclei were stained with a less bright blue fluorescence (due to the
Hoechst 33258 dye). Cells treated with VGB and gabapentin exhibited typical features of apoptosis
such as chromatin condensation. The condensed or fragmented chromatin were emitting
fluorescence in cells depicting vigabatrin (Figure 3 C and D) and gabapentin (Figure 3 E and F)
induced cell apoptosis. The cells treated with taxifolin, silychristin, silydianin, silybin, isosilybin
and taurine along with VGB and gabapentin had no condensed nuclei indicating the drugs
prevented apoptosis and decreased cell toxicity.
The DeadEnd™ Fluorometric TUNEL (Terminal deoxynucleotidyl transferase dUTP)
System was used for specific detection of R28 and ARPE-19 apoptotic cells. The fragmentation
of DNA is an important event in apoptosis of cell. The DeadEnd™ Fluorometric TUNEL System
incorporates fluorescein-12-dUridine triphosphate at 3´-OH DNA end of fragmented DNA of
apoptotic cells using the Terminal Deoxynucleotidyl Transferase recombinant enzyme 87. The cells
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treated with VGB and gabapentin increased the TUNEL-positive cells proportional to the
concentration of VGB and gabapentin compared to untreated cells. The apoptotic cells were
differentiated from late stages of necrotic cell death, by merging the Hoechst stain and labelled
with TUNEL system. The nuclear Hoechst’s stain accurately discriminated apoptotic cells from
cells that are in late-stage necrosis (Figure 5 and 6). The cells pretreated with taxifolin, silychristin,
silydianin, silybin and isosilybin depicted cells with nuclear condensation and fragmented DNA
were decreased compared to cells treated with VGB and gabapentin alone.
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Figure 3. Representative DAPI and bright field fluorescence images show morphological changes
of ARPE-19 cells detected with staining of Hoechst 33258. The images of cells untreated (A&B),
treated with 25 mM vigabatrin (C&D) and 50 mM Gabapentin (E&F) for 24 h and imaged by
fluorescence microscope (magnification 10X).
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Figure 4. Representative DAPI and bright field fluorescence images show morphological changes
of R28 cells detected with staining of Hoechst 33258. The images of cells untreated (A&B), treated
with 25 mM vigabatrin (C&D) and 15 mM Gabapentin (E&F) for 24 h and imaged by fluorescence
microscope (magnification 10X).
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Figure 5. Representative DAPI and GFP fluorescence images show morphological changes of ARPE-19 cells detected by staining
with Dead end TUNEL system and Hoechst 33258. The images of untreated cells (A1-A3), treated with vigabatrin (B1-B3) and
Gabapentin (C1-C3) for 24 h and imaged by fluorescence microscope (magnification10X).
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Figure 6. Representative DAPI and GFP fluorescence images show morphological changes of R28 cells detected by staining with
Dead end TUNEL system stain and Hoechst 33258. The images of untreated cells (A1-A3), treated with vigabatrin (B1-B3) and
Gabapentin (C1-C3) for 24 h and imaged by fluorescence microscope (magnification 10X).

3.3

Mitochondrial membrane potential assay
During normal cell conditions mitochondria maintains electrochemical proton gradient

across their membrane. The mitochondria are electronegative, membrane potential facilitates the
entry of cations and thus accumulation of cations in mitochondria favors synthesis of ATP. During
the apoptosis of cells, mitochondrial membrane is compromised and there is formation of pore
leading to decrease in membrane potential88. Hence, this mitochondrial membrane potential is
used as an indicator of cell health and to detect the apoptotic cells.
JC-1 dye is a cationic, lipophilic dye have a potential to enter healthy mitochondria and
form an aggregate to produce red-fluorescence, which can be analyzed at excitation and emission
wavelength of 540 and 570nm, respectively. In apoptotic cells, there is decrease in mitochondrial
membrane potential and JC-1 stains remain in cytosol in their monomeric form producing greenfluorescence, which can be analyzed at excitation and emission wavelength of 480 and 530nm,
respectively. The ratio of J-aggregates to J-monomers in ARPE-19 cells treated with VGB and
gabapentin were inversely proportional to the concentration of VGB and gabapentin treated to
cells (Figure. 7). The ratio of J-aggregates to J-monomers in cells pretreated with taxifolin (50
µM), silychristin (50 µM), silydianin (100 µM), silybin (50 µM), isosilybin (50 µM) and taurine
(10 mM) were increased in presence of VGB and gabapentin (Table. 2). These study results
demonstrate silymarin and taurine protects the cells from apoptosis induced by VGB and
gabapentin. In R28 cells, negligible changes in the ratio of J-aggregates to J-monomers cells were
observed when treated with VGB and gabapentin (Figure. 8). Negligible changes in mitochondrial
potential could be due to R28 cell death caused by necrotic pathway.
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Mitochondrial membrane potential assay
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Figure 7. Concentration dependent effect of vigabatrin and gabapentin on ratio of J-aggregates
to J-monomers in ARPE-19 cells (mean ± SD) n=6.
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Mitochondrial membrane potential assay
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Figure 8. Concentration dependent effect of vigabatrin and gabapentin on ratio of J-aggregates
to J-monomers in R28 cells (mean ± SD) n=6.
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Table 2. Effect of silymarin and taurine on changes in ratio of J-aggregates to J-monomers in
ARPE-19 cells produced by vigabatrin and gabapentin (mean ± SD) n=6.

Drug treatment

3.4

Ratio of J-aggregates to J-monomers in ARPE-19 cells
Vigabatrin (25 mM)

Gabapentin (25 mM)

Taxifolin (50 µM)

1.49 ± 0.19

1.25 ± 0.08

Silychristin (50 µM)

1.79 ± 0.08

1.33 ± 0.21

Silydianin (100 µM)

1.38 ± 0.13

1.14 ± 0.17

Silybin (50 µM)

1.88 ± 0.07

1.58 ± 0.29

Isosilybin (50 µM)

1.61 ± 0.11

1.80 ± 0.31

Taurine (10 mM)

1.15 ± 0.06

0.83 ± 0.10

No pretreatment

0.44 ± 0.09

0.67 ± 0.04

Blank

2.51 ± 0.32

2.77 ± 0.17

Detection of Reactive oxygen species generation
The amount of reactive oxygen species produced by R28 and ARPE-19 cells on exposure

to VGB, gabapentin and hydrogen peroxide was estimated using the oxidant-sensing fluorescent
probe 2′,7′-dichlorodihydrofluorescein diacetate (DCFH-DA). DCFH-DA is a lipophilic dye
converted to its nonfluorescent polar derivative DCFH by esterase present in cells and these
derivative gets oxidized to highly fluorescent DCF by intracellular ROS and other peroxides89.
The ROS in ARPE-19 and R28 cells treated with hydrogen peroxide at 0.3- and 0.1-mM
concentration, respectively was considered as 100 %. The ROS in ARPE-19 cells treated with
vigabatrin (25 mM) and gabapentin (50 mM) was 92.4 % and 73 %, respectively. The vigabatrin
induced ROS in ARPE-19 cells pretreated with silymarin and taurine were decreased significantly
as shown in Figure 9, in following order, taxifolin > silydianin > silybin > silychristin > isosilybin
> taurine. The ROS in R28 cells treated with vigabatrin (25 mM) and gabapentin (15 mM) was
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83.1 % and 73 %, respectively. The vigabatrin induced ROS in R28 cells pretreated with silymarin
and taurine were decreased significantly as shown in Figure 10, in following order, taxifolin >
silybin > silychristin > isosilybin > silydianin > taurine. The antioxidants silymarin protected R28
cells from ROS highly efficiently compared to taurine.
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Figure 9. Effect of taxifolin (100 µM), silychrsitin (100 µM), silydianin (100 µM), silybin (100 µM), isosilybin (100 µM) and
taurine (10 mM) on ROS generated by gabapentin (25 mM), vigabatrin (50 mM) and hydrogen peroxide (0.3 mM) exposure in
ARPE-19 cells (mean ± SD) n=6.
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Figure 10. Effect of taxifolin (100 µM), silychrsitin (100 µM), silydianin (100 µM), silybin (100 µM), isosilybin (100 µM) and
taurine (10 mM) on ROS generated by gabapentin (15 mM), vigabatrin (25 mM) and hydrogen peroxide (0.3 mM) exposure in R28
cells (mean ± SD) n=6.

3.5

Cytoprotective effect
The cytoprotective effect of different concentrations of silymarin and taurine on VGB,

gabapentin and hydrogen peroxide induced R28 and ARPE-19 cellular toxicity were evaluated.
The R28 cells exposed to 25 mM of VGB for 24 hours produced cytotoxicity of 53.2 ± 0.93% (cell
viability of 46.8 %). Pretreatment of cells with taxifolin (50 µM), silychristin (100 µM), silydianin
(100 µM), silybin (25 µM), isosilybin (50 µM) and taurine (5 mM) increased the cell viability to
92.9 ± 10.7, 105 ± 3.60, 65.0 ± 8.72, 104 ± 1.97, 101 ± 4.26 and 95.0 ± 10.3%, respectively in
presence of 25 mM vigabatrin (Figure 11A and 11D).
The R28 cells exposed to 15 mM of gabapentin for 24 hours produced cytotoxicity of 46.5
± 1.23% (cell viability of 53.5 %). Pretreatment of cells with taxifolin (50 µM), silychristin (25
µM), silydianin (100 µM), silybin (100 µM), isosilybin (100 µM) and taurine (2.5 mM) increased
the cell viability to 99.8 ± 5.18, 92.0 ± 3.79, 79.8 ± 4.38, 91.1 ± 7.68, 88.7 ± 4.19 and 99.5 ±
5.14%, respectively in presence of 15 mM gabapentin (Figure 11B and 11D).
The R28 cells exposed to 0.1 mM of hydrogen peroxide for 24 hours produced cytotoxicity
of 68.2 ± 7.56% (cell viability of 31.8 %). Pretreatment of cells with taxifolin (100 µM),
silychristin (100 µM), silydianin (100 µM), silybin (100 µM), isosilybin (100 µM) and taurine (10
mM) increased the cell viability to 72.8 ± 5.81, 76.3 ± 3.60, 56.8 ± 5.72, 75.7 ± 4.23, 75.9 ± 4.75
and 93.2 ± 6.69%, respectively in presence of 0.1 mM hydrogen peroxide (Figure 11C and 11D).
The ARPE-19 cells exposed to 25 mM of vigabatrin for 24 hours produced cytotoxicity of
47.7 ± 12.7 % (cell viability of 52.3 %). Pretreatment of cells with taxifolin (25 µM), silychristin
(25 µM), silydianin (100 µM), silybin (100 µM), isosilybin (50 µM) and taurine (5 mM) increased
the cell viability to 93.9 ± 1.32, 93.2 ± 0.67, 81.7 ± 2.35, 86.9 ± 1.57, 99.9 ± 9.85 and 93.4 ±
1.50%, respectively in presence of 25 mM vigabatrin (Fig. 12A and 12D).
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The ARPE-19 cells exposed to 50 mM of gabapentin for 24 hours produced cytotoxicity
of 51.6 ± 8.72% (cell viability of 49.4 %). Pretreatment of cells with taxifolin (25 µM), silychristin
(50 µM), silydianin (100 µM), silybin (50 µM), isosilybin (100 µM) and taurine (10 mM) increased
the cell viability to 95.1 ± 9.51, 98.1 ± 8.89, 101 ± 21.1, 90.0 ± 9.98, 99.4 ± 7.66 and 86.2 ± 4.72%,
respectively in presence of 50 mM gabapentin (Fig. 12B and 12D).
The ARPE-19 cells exposed to 0.3 mM of hydrogen peroxide for 24 hours produced
cytotoxicity of 49.6 ± 7.56% (cell viability of 50.4 %). Pretreatment of cells with taxifolin (100
µM), silychristin (50 µM), silydianin (100 µM), silybin (25 µM), isosilybin (25 µM) and taurine
(10 mM) increased the cell viability to 80.8 ± 7.51, 104 ± 10.7, 70.5 ± 1.56, 106 ± 7.80, 104 ± 9.03
and 93.0 ± 3.01%, respectively in presence of 0.3 mM hydrogen peroxide (Fig. 12C and 12D).
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Figure 11. The cytoprotective effect of different concentrations of silymarin (A, B and C) and taurine (D) on vigabatrin, gabapentin and
hydrogen peroxide produced R28 cellular toxicity (mean ± SD) n=6.
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Figure 12. The cytoprotective effect of different concentrations of silymarin (A, B and C) and taurine (D) on vigabatrin, gabapentin and
hydrogen peroxide produced ARPE-19 cellular toxicity (mean ± SD) n=6.

4.

Conclusions
The results indicate vigabatrin and gabapentin are toxic for retinal neuronal and pigment

epithelial cells in concentration dependent manner compared to topiramate and tiagabine. The
mechanism of cell death on exposure to VGB and gabapentin to retinal neuronal and epithelial cells
are different. In ARPE-19 cells, VGB and gabapentin has shown clear chromatin condensation,
DNA fragmentation and decrease membrane potential leading to apoptotic cell death as major path.
In R28 cells, the decrease in membrane potential was not clear and thus indicating oxidative
pathway as major cause leading to direct necrosis. The study results speculate major reason for
VGB, and gabapentin induced retinal cell toxicity was ROS generation. Silymarin and taurine
constituents decreased VGB and gabapentin induced cell toxicity. The mechanism of cytoprotective
action of silymarin and taurine are due to decrease in ROS in R28 and ARPE cells. The silymarin
and taurine can be used as supplement or adjuvant in the treatment of seizure to prevent the ocular
adverse events caused by chronic use of antiepileptic agents.
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Profile
 Doctoral research focused on exploring retinal drug transport mechanism and novel drug delivery
approaches to alleviate drug induced retinal toxicity.
 Over 8 years of experience in pharmaceutical industry and academic research encompassing in-vitro,
ex-vivo, in-vivo and bioanalytical skills.
 Expertise in designing in-vitro ADME assays, preclinical formulation development and
pharmacokinetic studies of new chemical entities (NCE’s) to facilitate lead candidate selection and
optimization.

Educational Qualifications
PhD in Pharmaceutical
sciences GPA 3.88 (scale of 4)
Master
of
(Pharmacology)

pharmacy

University of Mississippi, Department of
Pharmaceutics and Drug delivery,
Mississippi, US
Kakatiya University, Warangal, India

2016
Present

–

2008 – 2010

Research Experience
 Graduate Research assistant
(Jan 2016 to Present)
University of Mississippi, MS
 Alleviated vigabatrin induced retinal toxicity by nose to brain drug delivery.
 Explored role of transporters in vigabatrin retinal accumulation.
 Developed assay to evaluate in-vitro skin intrinsic clearance of drugs using human skin models.
 Developed novel anandamide topical formulation for alleviating peripheral neuropathic pain.
 Drug metabolism Intern
(June 2019 -Aug 2019)
Pharmacyclics, Sunnyvale, CA
 Evaluated species difference in the drug clearance pathway mechanisms.
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 Drug metabolism Intern
(June 2018 -Aug 2018)
Pharmacyclics, Sunnyvale, CA
 Established methods to predict human and rat in-vivo clearance of covalent Bruton’s tyrosine kinase
inhibitors using ADME properties.
 Implemented microsomal binding assay to facilitate clearance prediction.
 Evaluated hepatocyte clearance, CYP-inhibition assays, blood binding, and protein binding assays
to accelerate targeted covalent inhibitor drug discovery research.
 Interpreted ADME data of targeted covalent inhibitors.
 Research Associate
(Feb 2011 - Jan 2016)
DMPK department in Jubilant Biosys, India.
 Contributed for IND filing of EN3356 (Endo pharmaceuticals collaboration-2013) a novel
CYP17A inhibitor for the treatment of metastatic castration resistant prostate cancer.
 Implemented CYP450 enzymes kinetic assays for determination of Km, Ki and Kinact.
 Expertise in designing and interpretation of in-vitro ADME assays and in-vivo preclinical
pharmacokinetic, tissue distribution, ocular pharmacokinetic and mass balance studies for drug
discovery programs.
 Presented DMPK data in cross functional team meetings.
 Developed and validated HPLC and LC-MS/MS bioanalytical methods for generic compounds and
NCE’s as per the regulatory guidelines.

Technical expertise














Evaluation of physicochemical properties of NCE’s.
Metabolic stability studies in microsomes, S9 fractions and hepatocytes.
High throughput CYP450 inhibition assays.
Protein binding assays (EQD).
Caco2 and MDR1-MDCK permeability assays.
Cell based drug transport kinetic assays.
Cell based assays in retinal pigmental epithelial, neuronal and human epidermal keratinocytes.
Metabolite profiling of NCE’s.
PO, IP, IM, SC, IV and intranasal dosing in preclinical species.
CSF collection from cisterna magna in rats.
Subconjunctival and intravitreal (ocular) pharmacokinetics in rats and rabbits.
In-vitro skin permeation studies.
Formulation development for oral, topical and intranasal drug delivery.

Instrumentation expertise



LC-MS/MS (Waters Xevo TQD, X500 QTOF Sciex, API-4000, API-5500 and Thermo).
HPLC (Shimadzu), Waters alliance 2996 and Waters Acuity UPLC.
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Software Proficiency


Graph pad prism, Phoenix (Pharmacokinetic calculations), Analyst (AB Sciex), SciexOS (Sciex
QTOF), Mass lynx (Waters), LC solutions (Shimadzu) and Empower (Waters HPLC).

Awards and Recognition
 Received first place for poster entitled ‘Anandamide Topical Delivery for Management of Pain’ in
8th annual research symposium 2018 at University of Mississippi.
 Received Graduate Student Council Research Grant for 2017 funded by Graduate Student Council
of The University of Mississippi for project entitled ‘Topical anandamide gel for pain management’.
 Received travelship award from American Association of Pharmaceutical Sciences Annual
Meeting and Exposition 2017 in San Diego, CA.
 Initiated as an active member of Chi chapter at University of Mississippi in 2017 for “Rho Chi Honor
Society” for outstanding academic excellence.
 Recognized and awarded as Emerging associate-2013 by Jubilant Biosys, for significant contribution
and execution of in-vitro ADME assays.
 Recognized and awarded as Best Team Player by Jubilant Biosys for integrated discovery projects for
the year 2012 (Endo pharmaceuticals), 2013 (Norgine) and 2014 (Mnemosyne).

Publications
 Anitha Police, Vijay Kumar Shankar, S. Narasimha Murthy. RP-HPLC Method for Simultaneous
Estimation of Vigabatrin, Gamma-Aminobutyric Acid and Taurine in Biological Samples. Journal of
chromatography B, 2018, 1076:44-53.
 Huy Dao, Prit Lakhani, Anitha Police, Venkataraman Kallakunta, Sankar Srinivas Ajjarapu, Kai-Wei
Wu, Pranav Ponkshe, Michael A. Repka, and S. Narasimha Murthy. Microbial Stability of
Pharmaceutical and Cosmetic Products. AAPS PharmSciTech, 2018, 19(1):60-78.
 Ravi Kanth Bhamidipati, Sandip Guav, Anitha police, Zainuddin Mohd, Sriram Rajagopal, Ramesh
Mullangi. The human pharmacokinetics of odanacatib, a novel cathepsin K inhibitor, predicted by
interspecies scaling: a retrospective analysis. International Journal of Pharmacokinetics, 2017, 2(1); 4755.
 Vinod A B, Anitha Police, Rakesh Hiremath, Anusha Raj, Suresh P Sulochana, Devaraj V C,
Zainuddin Mohd, Ravi Kanth Bhamidipati, Ramesh Mullangi. Preclinical assessment of ulixertinib, a
novel ERK1/2 inhibitor. ADMET and DMPK, 2017, 5(4): 212-23.
 Suresh PS, Anitha Police, Rajnish Kumar, Mohd Zainuddin, Purushottam Dewang, Ragahava Reddy
Kethiri, Sriram Rajagopal and Ramesh Mullangi. Simultaneous Determination of Abiraterone and Its
Novel Active Metabolite, D4A by LC-MS/MS in Mice Plasma and Its Application to a Pharmacokinetic
Study. Journal of Research Analytica, 2016; 2(1); 25-33.
 Mohd Zainuddin, A B Vinod, Sandip Dhondiram Gurav, Anitha Police, Avinash Kumar, Chandan
Mithra, Purushottam Dewang, Raghava Reddy Kethiri, Ramesh Mullangi. Preclinical assessment of
Orteronel(®), a CYP17A1 enzyme inhibitor in rats. European Journal of Drug Metabolism and
Pharmacokinetics, 2016, 41(1): 1-7.
 Suresh PS, Rajnish Kumar, Anitha Police, Mohd Zainuddin and Ramesh Mullangi. Simultaneous
Quantitation of Rifampicin and Piperine in Rat Plasma by a Selective and Sensitive Liquid
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Chromatography-Tandem Mass Spectrometric Method and Its Pharmacokinetic Application. Journal
of Research Analytica, 2015; 1(1); 31-8.
Anitha Police, Sandip Gurav, Vinay Dhiman, Mohd Zainuddin, Ravikanth Bhamidipati, Sriram
Rajagopal, Ramesh Mullangi. Development and validation of a RP-HPLC method for the quantitation
of odanacatib in rat and human plasma and its application to a pharmacokinetic study. Biomedical
Chromatography, 2015, 29(11): 1664-69.
Sandip Gurav, Anitha Police, Mohd Zainuddin, Ravindra Ramachandra Punde, Purushottam Dewang,
Chandregowda V, Raghava Reddy Kethiri, Sriram Rajagopal, Ramesh Mullangi. Development and
validation of an enantioselective LC-MS/MS method to quantify enantiomers of (±)-TAK-700 in rat
plasma: lack of in vivo inversion of (+)-TAK-700 (Orteronel) to its antipode. Biomedical
Chromatography, 2013, 27: 164-71.
Kuldeep Sharma, Anitha Police, Avinash Kumar, Gopal V Pawar, Sanjeev Giri, Sriram Rajagopal,
Ramesh Mullangi. Development and validation of an LC-MS/MS-ESI method for the determination of
lorglumide, a CCK-1 antagonist in mouse plasma: application to a pharmacokinetic study. Biomedical
Chromatography, 2012, 26(7):833-38.
Sandip Gurav, Anitha Police, Mohd Zainuddin, Junaid Hassan Farooqui, Krishna Reddy G, Raghava
Reddy Kethiri, Sriram Rajagopal, Ramesh Mullangi. Development and validation of a highly sensitive
LC–ESI-MS/MS method for the determination of Orteronel® (TAK-700) in rat plasma: application to
a pharmacokinetic study. Bioanalysis, 2012; 4(12):1471-80.

Publications under communication
 Anitha Police, Vijay Kumar Shankar, S. Narasimha Murthy. Role of Taurine Transporter in Retinal
Uptake of Vigabatrin.
 Anitha Police, Vijay Shankar, Pankaj Pandey, Robert Doerksen, S. N. Murthy. Development and
Evaluation of novel anandamide topical formulation for peripheral neuropathic pain.
 Vijay Kumar Shankar, Anitha Police, Pankaj Pandey, Zachary Cuny, Robert J. Doerksen, S. Narasimha
Murthy. Optimization of Sulfobutyl-Eher- β-Cyclodextrins Levels in Oral Formulation to Enhance
Progesterone Bioavailability.
 Vijay Kumar Shankar, Anitha Police, Pankaj Pandey, Zachary Cuny, Robert J. Doerksen, S. Narasimha
Murthy. Oral bioavailability enhancement of silymarin constituents using SBE-β-CD.

Posters Presented
 Presented poster in 43rd Annual Conference of Indian Pharmacological Society conducted by National
Institute of Nutrition, Hyderabad 2010, entitled “Effect of Nicardipine on the pharmacokinetics and
pharmacodynamics of Pioglitazone in normal and diabetic rats”.
 Presented poster in AAPS conference 2016, Denver; titled “RP-HPLC method for simultaneous
determination of vigabatrin, GABA and taurine in different biological tissues”.
 Presented poster in annual neuroscience research day conference at UMMC 2017 entitled “Nose to
brain drug delivery approach for alleviating retinal neuronal toxicity of vigabatrin”.
 Posters presented at AAPS annual conference, San Diego, CA., 2017
 Approaches to Alleviate Antiepileptic Drug Induced In-vitro Retinal Neuronal Toxicity.
 Thermo Sensitive Gel for Intranasal Delivery of Vigabatrin.
 Anandamide topical delivery for management of pain.
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 Presented poster entitled ‘Anandamide Topical Delivery for Management of Pain’ on March 20th, 2018
in research day 8th annual research symposium at University of Mississippi.
 Posters presented at AAPS annual conference, Washington DC, 2018
 Role of Taurine Transporter in Retinal Uptake of Vigabatrin.
 Inhibition of Anandamide Metabolism in In-Vitro Human Skin Model.
 Effect of anti-oxidants on vigabatrin induced retinal cell toxicity.
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